Medical University of South Carolina

MEDICA
MUSC Theses and Dissertations
2016

Covariate Adjustment in Non-Inferiority Trials: Implications for
Type I Error
Katherine Nicholas
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/theses

Recommended Citation
Nicholas, Katherine, "Covariate Adjustment in Non-Inferiority Trials: Implications for Type I Error" (2016).
MUSC Theses and Dissertations. 407.
https://medica-musc.researchcommons.org/theses/407

This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact
medica@musc.edu.

Acknowledgements
I would like to thank all of the wonderful people who have made this work
possible including my friends and family who have stuck with me through all of
the trials and tribulations of graduate school, my major advisor and dissertation
committee for sharing their time and their ideas, Ms. June Watson for always
keeping me on track throughout the process, and my fellow students for sharing
their strengths and their support. I would also like to acknowledge the support of
my research funding via the Neurological Emergencies Treatment Trial Network
(U01NS059041) funded by the National Institute of Neurological Disorders and
Stroke (NINDS) without which none of this would have been possible.

i

Table of Contents
Abstract
1. Introduction ..........................................................................................................1
1.1 Motivating Example...............................................................................3
1.2 Specific Aims .........................................................................................5
2. Review of Literature ............................................................................................9
2.1 Non-Inferiority Trials.............................................................................9
2.2 Randomization .....................................................................................15
2.3 The Impact of Failing to Adjust for Covariates in the Analysis ..........18
2.4 The Impact of Tests of Baseline Imbalance .........................................22
2.5 Quantifying the Impact of Adjustment for a Given Covariate Based on
Influence and Disparity ..................................................................25
3 Aim1: The Impact of Covariate Adjustment at randomization and Analysis for
Binary Outcomes: Understanding Difference between Superiority and
Non-Inferiority Trials.................................................................................30
3.1 Introduction ..........................................................................................31
3.2 Existing Literature ...............................................................................33
3.3 Simulation Studies ...............................................................................35
3.3a Simulation Parameters ...........................................................35
3.3b Simulation Strategy................................................................37
3.4 Simulation Results ...............................................................................39
3.4a Superiority ..............................................................................39
3.4b Non-Inferiority .......................................................................40
ii

3.5 Discussion ............................................................................................42
4. Aim 2: Choosing Covariates for Adjustment in Non-Inferiority Trials with
Binary Outcomes Based on Influence and Disparity .................................46
4.1 Introduction ..........................................................................................47
4.2 Existing Literature ...............................................................................50
4.3 Extension to Non-Inferiority Setting ...................................................53
4.4 Relative Importance of 𝑟1and 𝑟2 ..........................................................55
4.5 Relationship to Bias .............................................................................61
4.6 Implications for Error ..........................................................................63
4.7 Simulation Practical Use ......................................................................66
4.8 Discussion ............................................................................................68
5. Aim 3: Application of a Joint Statistic for Influence and Disparity in the
Identification of Baseline Covariates Required in Analysis of
Non-Inferiority Trials.................................................................................70
5.1 Introduction ..........................................................................................71
5.2 Existing Literature ...............................................................................72
5.3 Application ...........................................................................................75
5.3a RAMPART ............................................................................75
5.3b RAMPART Pediatric Population ...........................................82
5.4 Discussion ............................................................................................88
6. Overall Conclusions ...........................................................................................91
References ..............................................................................................................93
iii

Lists of Tables
Table 2.5.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate .......26
Table 4.2.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate .......51
Table 4.3.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate
with Treatment Effect Equal to Non-Inferiority Margin (𝑑) ......................53
Table 5.3a.1: Statistics and Treatment Estimates by Covariate for RAMPART.
Each Model Contained Treatment Plus One Covariate .............................77
Table 5.3b.1: Statistics and Treatment Estimates by Covariate for Pediatric SubPopulation of RAMPART. Each Model Contained Treatment Plus One
Covariate ....................................................................................................84

iv

Lists of Figures
Figure 3.4a.1 Operating Characteristics for Covariate Adjustment
in Superiority Trials ...................................................................................40
Figure 3.4b.1 Operating Characteristics for Covariate Adjustment
in Non-Inferiority Trials ............................................................................42
Figure 4.4.1 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when
𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 .........................................................................56
Figure 4.4.2 ZC*-ZA for Reduced Range of 𝑟1 and 𝑟2 when
𝑁 = 388 𝑝 = 0.4, 𝑑 = 0.1 .........................................................................58
Figure 4.4.3 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when
𝑁 = 199, 𝑝 = 0.1, 𝑑 = 0.1 .........................................................................60
Figure 4.5.1 Bias for Full Range of 𝑟1 and 𝑟2 when
𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 .........................................................................62
Figure 4.6.1 Change in Width of the 95% Confidence Interval
for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 ..................64
Figure 4.6.2 Movement of the 95% Confidence Interval Given Adjustment and
Implications for Error Probabilities in Non-Inferiority Trials ...................65
Figure 4.7.1: Ranking of Covariates with All Possible Combinations of Full
Range of 𝑟1and 𝑟2 where 𝑁 = 388, 𝑝 = 0.4, and 𝑑 = 0.1 ........................66
Figure 4.7.2: Random Subsets of Ten Covariates from Figure 4.7.1 ....................67
Figure 5.3a.1: Treatment Estimates and 95% Confidence Intervals for Covariates
in RAMPART. Each Model Contains Treatment Plus One Covariate…..79
Figure 5.3a.2: Z Importance for Covariates in RAMPART ..................................80
Figure 5.3a.3: Impact of Adjustment Using Z Importance in RAMPART ...........81
Figure 5.3b.1 Treatment Estimates and 95% Confidence Intervals for
Covariates in Pediatric Sub-Population of RAMPART. Each Model
Contains Treatment Plus One Covariate ....................................................85
Figure 5.3b.2: Z Importance for Covariates in Pediatric Sub-Population of
RAMPART ................................................................................................86
Figure 5.3b.3: Impact of Adjustment Using Z Importance in Pediatric
Sub-Population of RAMPART ..................................................................88
v

Abstract

There has been little work to date regarding the proper use of covariate
information in non-inferiority trials. Too often knowledge obtained in the
superiority setting is applied directly to the non-inferiority setting. However, due
to the reversal of the hypotheses and the consequent reversal of the implication of
error probabilities, this is a dangerous practice. The current work demonstrates
that in both superiority and non-inferiority, failure to adjust for important
covariates results in estimates of treatment effect that are biased towards zero with
standard errors that are deflated. However, as no treatment difference is
approached under the null hypothesis in superiority and under the alternative in
non-inferiority, this results in decreased power and nominal or conservative
(deflated) type I error in the context of superiority, but inflated power and type I
error

under

non-inferiority.

This

occurs

regardless

of

adjustment

at

randomization.
Generally, it is advised that covariates requiring adjustment be specified
before the start of the trial. However, important prognostic factors are not always
vi

known in advance. Thus, a joint statistic for the identification of important
covariates based on the simultaneous assessment of influence on outcome and
disparity across treatment groups is developed for the non-inferiority setting. This
statistic, when calculated for all available covariates in a trial, can be used to rank
them according to importance. This ranking can be used to identify the subset that
will optimize the tradeoff between the change in the point estimate of the
treatment effect and its precision while preserving type I error. This method is
applied to the Rapid Anticonvulsant Medication Prior to Arrival Trial
(RAMPART) and its pediatric cohort.

vii

Chapter 1
Introduction

With the increase in the number of efficacious therapies available, the
non-inferiority trial is growing progressively more popular. It is often used when
a current standard of care has already been shown to be effective, but an
alternative many offer some added benefit such as lower cost, greater ease of
administration, or greater tolerability.

Thus, a non-inferiority trial seeks to

address the question of whether a new drug or intervention is “no worse than” a
current standard of care by some predetermined margin, the non-inferiority
margin. Under this design, the null hypothesis states that the new drug is worse
than the standard and the alternative states that it is nearly equal by some predefined amount.5 These hypotheses are often formally tested using a confidence
interval approach in which the null is rejected if the lower bound crosses the predetermined non-inferiority margin.13,21 Due to this reversal in the hypotheses, the
implications of type I and type II error are also reversed.5 An FDA guidance41
exists for non-inferiority trials, which outlines several key design issues including
1

the proper specification of hypotheses, the choice of active control, the
determination of the non-inferiority margin, and the appropriate analysis method.
However, gaps remain in this guidance as well as in the statistical and clinical
literature, including recommendations for the proper use of covariate information.
In a PubMed search of phase-III clinical trials published in the last 10
years containing the word “non-inferiority”, 44.8% of 58 trials utilized complete
randomization

and

unadjusted

primary

analyses.

Covariate

adjusted

randomization and appropriate analysis of covariance or stratification was used in
20.7% of trials. Covariate adjustment at randomization, but not at analysis was
done in 25.7%, and adjustment at analysis but not at randomization was done in
8.6% of the trials.

This review of current practice shows that there is still

considerable variability in the way that clinical trialists use covariate information,
a finding that is not surprising considering the lack of attention it has received in
the non-inferiority literature. Some feel that primary analyses should always be
unadjusted as this offers greater interpretability. Others believe that tests of
baseline imbalance can be used to determine which covariates require adjustment,
while still others argue that all known prognostic covariates should be included at
both randomization and analysis.1,31,32,35,36
An issue arises, however, when important prognostic variables are not
known in advance. In this case, a data-driven method for choosing covariates
based on both disparity with treatment allocation and influence on outcome is of
2

value. This can be accomplished through a joint statistic that combines these two
factors to maximize the tradeoff between the change in the point estimate itself
and its precision.3,6,7 While such data-driven techniques could have important
implications for type I error, the statistic can be designed to reduce this potential
such that covariates with disparity and influence in the same direction are favored.
Thus, the treatment estimate is always conservative. In practice, this statistic can
be calculated for all available covariates in a trial and ranked according to
importance of inclusion in analysis to this end. This work seeks to address (1) the
impact of failing to adjust for prognostic covariates at either randomization or
analysis in a non-inferiority trial, (2) the development of the joint statistic for
disparity and influence, and (3) the practical implications of its use as further
outlined in the specific aims.

1.1 Motivating Example
This issue presented itself to the Neurologic Emergencies Treatment Trials
(NETT) Network during the design of the Rapid Anticonvulsant Medication Prior
to Arrival Trial (RAMPART). RAMPART is a non-inferiority trial in the prehospital treatment of status epilepticus, which is a life threatening and debilitating
disease operationally defined as a seizure lasting for at least five minutes. The
current FDA approved treatment for status epilepticus is intravenous (IV)
lorazepam (4mg-10mg), but as it is difficult to establish an IV in a patient that is
3

actively seizing, there is a need for an equally effective therapy with a simpler
method of administration. Intramuscular (IM) administration of a benzodiazepine
had shown promise as an alternate approach, but was not expected to yield
superior efficacy. As such, RAMPART was designed to test the hypothesis that
IM midazolam (10 mg in adults or 5 mg in children < 13 kg) was non-inferior to
IV lorazepam (4 mg in adults or 2 mg in children < 13 kg) by a pre-specified
clinically meaningful amount, the non-inferiority margin. The primary outcome
was the proportion of subjects with seizure termination prior to emergency
department (ED) arrival without the use of rescue medication. A total of 893 adult
and pediatric patients were enrolled.40
The RAMPART trial had many unique aspects including administration of
treatment in a pre-hospital setting. This required extensive training of the
Emergency Medical Services (EMS) units across the US and the need to have
study drug available on each ambulance, making it infeasible to include
prognostic factors in the randomization algorithm.

Therefore, subjects were

allocated via complete randomization, without consideration of any potentially
important prognostic variables, and an unadjusted primary analysis was
conducted.40
Upon completion of the trial, not only was IM midazolam found to be
non-inferior to IV lorazepam (Π𝐼𝑉 = 63.6%, Π𝐼𝑀 = 73.4%, 𝑝 < 0.001), but
results suggested superiority (p<0.001), implying that a change in clinical practice
4

may be warranted.39 There were, however, a number of covariates in this trial that
may have been of prognostic importance, and the exclusion of these covariates
from the analysis may have had serious implications in the accuracy of the
estimation of the treatment effect as well as the overall conclusions regarding IM
midazolam’s non-inferiority to IV lorazepam.

1.2 Specific Aims
As the impact of covariate adjustment in the non-inferiority setting is less
understood than in the context of superiority, it is of interest to evaluate the
impact of failing to include covariates in the analysis of non-inferiority trials and
to develop a method to aid in the decision to include covariates. Thus, the aims of
this dissertation are:
1.) To evaluate differences in the operating characteristics (power, type I
error, and bias in the treatment estimate as well as its accompanying
standard error) in the superiority and non-inferiority settings under the
following four scenarios:
a. Complete randomization and unadjusted analysis
b. Complete randomization and adjusted analysis
c. Covariate adjusted permuted block randomization and unadjusted
analysis

5

d. Covariate adjusted permuted block randomization and adjusted
analysis

Hypotheses:
For the superiority setting, we hypothesize a reduction in type I
error probability when covariate adjusted permuted block randomization is
used with an unadjusted primary analysis (Scenario 1c), and nominal type
I error for all other scenarios. Furthermore, we expect to see greater
preservation of power in adjusted analyses as compared to unadjusted
analyses, with additional preservation occurring in the context of covariate
adjusted randomization (Scenario 1d). As for bias, we hypothesize
estimates of treatment effect and standard errors that are biased downward
toward zero in the context of unadjusted analyses, with greater bias in the
standard error of the treatment estimate when complete randomization is
used.

However, we expect minimal bias in the context of adjusted

analyses.
In the non-inferiority setting, we expect a reversal such that type I
error is inflated for Scenario 1c (nominal for all other scenarios) and
power is inflated for covariate adjusted randomization and analyses.
Similarly, we hypothesize that treatment estimates will be biased upward
toward zero and the accompanying standard error biased downward in the
6

context of unadjusted analysis, with greater bias in the standard error of
the treatment estimate in the context of complete randomization. In
addition, we expect minimal bias in the context of adjusted analyses.

2.) To develop a joint statistic to quantify the impact of adjustment for a given
binary covariate based on its association with outcome (influence) and its
imbalance across treatment groups (disparity)

Hypotheses:
We believe that the work of Canner6,7 and Beach and Meier3 can
be extended for use in the non-inferiority framework with a binary
outcome through the introduction of the non-inferiority margin.

We

expect that this statistic will fully quantify the impact of adjustment for a
given covariate and can be used to rank available covariates in terms of
relative importance.

Finally, by choosing an appropriate subset of

covariates to include in analysis based on this ranking, we believe that
we can optimize reduction in type I error.

7

3.) To apply this statistic to rank the available covariates in a real trial
application and evaluate the impact of adjustment on the estimate of
treatment effect

Hypotheses:
We believe that, when applied to the RAMPART study as a whole
and also to the pediatric subset, the joint statistics developed in Aim 2 will
be able to identify the most appropriate subset of covariates to include in
the analysis. We also believe that inclusion of these covariates will result
in an estimate of treatment effect that is more precise and more
conservative in terms of type I error.

8

Chapter 2
Review of Literature

2.1 Non-Inferiority Trials
Non-inferiority trials are typically used in situations in which a standard of
care has already been established to be superior to placebo. However, a new
treatment may provide potential advantages, such as a reduction in costs, greater
ease of administration, or fewer side effects.

In such a situation, this new

candidate therapy may not be expected to be superior to standard of care, but if it
alleviates some of the limitations and is “no worse” by some pre-specified
amount, then it may be adopted by the clinical community.

Thus, a non-

inferiority trial seeks to provide a statistical answer to this question of “no worse
than” by showing that the experimental treatment is non-inferior to the standard of
care by some pre-specified amount, referred to as the non-inferiority margin (𝑑).
There are many challenges that arise in the design and analysis of such a trial
including the proper specification of hypotheses, the determination of the
probability of success in the standard of care group and the non-inferiority
9

margin, the appropriate analysis method to employ, and the impact of covariate
adjustment.
A fundamental difference between a superiority trial and a non-inferiority
trial is the way in which hypotheses are stated.5 The typical null hypothesis for a
one-sided superiority trial is that the difference is less than or equal to zero,
whereas the alternative hypothesis is that the difference is greater than zero
(experimental treatment is superior to placebo):
𝐻0 ∶ 𝜋𝑇 − 𝜋𝑃 ≤ 0 𝑜𝑟 𝜋𝑇 ≤ 𝜋𝑃
𝐻1 ∶ 𝜋𝑇 − 𝜋𝑃 > 0 𝑜𝑟 𝜋𝑇 > 𝜋𝑃
where 𝜋𝑇 is the probability of success in the treatment group and 𝜋𝑃 is the
probability of success in the placebo group. In the framework of a non-inferiority
trial, the null hypothesis is that the difference between the efficacy of the new
treatment (𝜋𝑇 ) and standard of care (𝜋𝑆 ) is less than or equal to the noninferiority margin (δ) versus the alternative hypothesis which states that this
difference is greater than δ:
𝐻0 ∶ 𝜋𝑇 − 𝜋𝑆 ≤ −𝑑 𝑜𝑟 𝜋𝑇 ≤ 𝜋𝑆 − 𝑑
𝐻1 ∶ 𝜋𝑇 − 𝜋𝑆 > −𝑑 𝑜𝑟 𝜋𝑇 > 𝜋𝑆 − 𝑑
When the hypotheses are stated in terms of probabilities of success as above, the
non-inferiority margin is often negative because we expect the new treatment to
be less efficacious than the standard of care under the null.5 However, if the
10

hypotheses are stated in terms of the proportion of failures in each treatment
group, then we would expect a positive non-inferiority margin.
Regardless, we are not comparing the candidate treatment to a placebo as
this would be unethical in the presence of a viable treatment. Instead, we are
using the standard of care for our comparison.5 This forces us to make an
assumption about the probability of success in the standard of care group, which
we can only do in light of previous studies in the same patient population. This is
often referred to as the constancy assumption because we must assume that this
treatment effect is constant across studies.13,41 In addition, the lack of a placebo
group forces us to make the assumption of assay sensitivity, which assumes that,
had a placebo group been included, the standard of care would have shown this
same treatment effect in comparison. If non-inferiority is demonstrated, this
assumption can be evaluated, but never formally proven, through the comparison
of confidence intervals for standard of care in the current study and in the
historical study used to establish superiority over placebo.13,41
Another design challenge in a non-inferiority study is that of choosing the
proper non-inferiority margin (𝛿). In 2006, the Committee for Proprietary
Medicinal Products for Human Use (CHMP) guidelines10 suggested that using an
absolute difference in proportions of 10% is appropriate, whereas the FDA41,
borrowing from vaccine trials, proposed a stepwise function based on the
probability of success for the standard of care (𝜋𝑆 ) as follows:
11

𝜋𝑆 < 0.8 → 𝛿 = 0.20
0.8 ≤ 𝜋𝑆 < 0.9 → 𝛿 = 0.15
𝜋𝑆 ≥ 0.9 → 𝛿 = 0.10
Romel34 suggested a function that was similarly dependent on the reference
treatment effect, but that was continuous:
3

−0.223 √{𝜋𝑆 (1 − 𝜋𝑆 )}
The current practice in the determination of the non-inferiority margin requires
the investigator to place the experimental treatment on a continuum with the
effect of placebo at one end and the effect of standard of care at the other. Then,
the full distance from placebo to standard of care can be derived using the
constancy assumption, and the distance from experimental treatment to standard
of care, which is the non-inferiority margin, can be based on clinical relevance.
Finally, the distance between placebo and experimental therapy can be calculated
as11:
(1 − 𝛿) ∗ (𝜋𝑆 − 𝜋𝑃 )
All of the methods discussed previously deal with a non-inferiority margin based
on an absolute difference in proportions, a technique which Garrett18 condemns
for being dependent on the probability of success for standard of care, and offered
the use of the odds ratio as a viable alternative that is not subject to this constraint.
In this case, the margin corresponds to smaller absolute differences in proportions
when the reference probability of success approaches either 0 or 1, which is
12

consistent with the goals of the regulatory documents, and it is easily incorporated
into generalized linear models.
There has also been much debate in the statistical and clinical literature
about the best approach to analyze data from a non-inferiority trial. In 1977,
Dunnett and Gent12 proposed the following test statistic based on the
incorporation of the non-inferiority margin into the test for a difference in
proportions in the context of a superiority hypothesis:
𝑧=
where 𝑣𝑎𝑟(𝑝1 − 𝑝2 ) =

𝑝1 (1−𝑝1 )
𝑛1

+

𝑝1 − 𝑝2 − 𝛿
√𝑣𝑎𝑟(𝑝1 − 𝑝2 )
𝑝2 (1−𝑝2 )
𝑛2

, 𝑝𝑖 is the probability of success in

treatment i, 𝑛𝑖 is the number of patients in treatment 𝑖, and 𝑖 = 1,2. Another
hypothesis testing approach which has been proposed by Hung et al.21 and
endorsed by the FDA guidance41 combines information from the trial(s) of the
historical control versus placebo with information from the current non-inferiority
trial as follows:
𝑍=

̂𝑂 ) − 𝑙𝑜𝑔(𝑃
̂0 ))
𝑙𝑜𝑔(𝑇̂) − 𝑙𝑜𝑔(𝐶̂ ) − (1 − 𝜆)(𝑙𝑜𝑔(𝐶
2
2
+ (1 − 𝜆)2 𝜎𝑃𝐶
√𝜎𝑇𝐶
𝑂

where 𝑙𝑜𝑔(𝑇̂) − 𝑙𝑜𝑔(𝐶̂ ) is the log relative risk from the non-inferiority trial of
2
treatment versus standard of care with variance equal to 𝜎𝑇𝐶
, 𝑙𝑜𝑔(𝐶̂𝑂 ) −

̂0 ) is the log relative risk from the trial(s) of standard of care versus placebo
𝑙𝑜𝑔(𝑃
13

2
with variance equal to 𝜎𝑃𝐶
, and 𝜆 is the percent of standard of care effect which
𝑂

must be preserved.
Several confidence interval approaches have also been proposed in which
the lower bound of the two-sided 95% confidence interval for the effect of
treatment versus standard of care is compared to either (1) the point estimate of
the effect of standard of care versus placebo found in previous trials, (2) the upper
bound of the two-sided 95% confidence interval of the effect of standard of care
versus placebo, or (3) a pre-specified fixed margin of clinical significance. Either
of the latter two methods results in conservative or nominal type I error, whereas
the first can result in increased type I error due to the fact that the variance of the
effect of standard of care versus placebo is not considered, and thus appropriate
weight is not given to trials of different sizes.21,41 In light of these findings, the
current confidence interval approach is accomplished by calculating a two-sided
95% confidence interval of the risk difference, relative risk, or odds ratio of the
treatment effect, and comparing its lower bound to a non-inferiority margin.18
This technique is considered by many to be better than the typical hypothesis
testing approach because it offers additional information such as the estimates of
the minimum and maximum treatment effect.
The subject of covariate adjustment in non-inferiority trials remains
lacking in the literature. Since the statement of null and alternative hypotheses
yields a different implication for type I and type II errors when compared to the
14

framework of superiority, it is suspected that the impact of failure to adjust for
important covariates may also differ in this setting. In non-inferiority trials, type I
error (or α) is defined as claiming non-inferiority when the new treatment is
actually worse than the active control, and type II error (or β) is defined as
claiming lack of non-inferiority when the experimental treatment is non-inferior
to the active control.5 Because of this important difference, our understanding of
covariate adjustment cannot easily be extended from the superiority to the noninferiority setting. Thus, there is a great need to further evaluate the impact of
covariate adjustment on operating characteristics in the context of non-inferiority
trials.

2.2 Randomization
In clinical trials, the variability present in the outcome of interest is large
in comparison to the expected magnitude of the treatment effect. The act of
randomization seeks to control this variability through the elimination of selection
bias as well as accidental bias in treatment allocation. Selection bias can be
controlled by the introduction of randomness, which forms the basis for
probabilistic approaches to hypothesis testing.

However, randomization also

seeks to control accidental bias by ensuring that there are no systematic
differences between treatment groups.14,19,30,44 The type of randomization that is
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used affects the amount of resulting randomness and balance, which can impact
the estimation of treatment effect if not considered at the analysis phase.25,44
In complete (or simple) randomization, patients are assigned to treatment
groups with equal probability. This results in perfect randomness but can often
lead to groups of unequal size, especially given small sample sizes. In fact, when
we randomize N patients with probability p=0.5 to two treatment groups, the
probability that each group contains an equal number of patients is:
𝑁 1
𝑃[𝑋 = 𝑥] = (𝑁⁄ ) 𝑁
2 2
Thus, if N equals 100, the probability that randomization will yield exactly 50
patients per group is approximately 8%. Furthermore, given calculation of mean
and variance from the binomial distribution, the same scenario yields a 95%
confidence interval of the number of patients assigned to either Treatment A or
Treatment B as roughly equal to:
𝑁𝐴 𝑜𝑟 𝐵 ± 10
As such, we can expect more than a 60/40 imbalance in favor of one treatment
over the other 5% of the time.30
Permuted block randomization, as introduced by Hill19, is achieved by first
choosing a block size, which can be any multiple of the number of treatments to
be evaluated. Then, the order of treatment assignments within each block is
randomly permuted, such that perfect balance is achieved after the completion of
16

each block. Thus, if a trial consisted of two treatments (A and B) as discussed
previously, and a block size of two was chosen, treatment assignments within
each block could take the form of either AB or BA. In this manner, the maximum
imbalance that could result would be one, yet the proportion of deterministic
assignments would be 50%.30 Thus, permuted block randomization results in a
much tighter treatment balance than complete randomization, but with much less
randomness.44 When the block size is equal to the sample size, permuted block
randomization becomes a random allocation design. This results in near perfect
randomness (some deterministic assignments may occur for the last subject(s)
enrolled) as well as perfect balance at the conclusion of the trial.44
Any of the randomization strategies above can also be used in the presence
of important covariates. A prognostic covariate is any variable that is significantly
associated with outcome, and the exclusion of such factors from the
randomization scheme or analysis may have important implications for a test of
treatment effect. Thus, when there is a known prognostic covariate, adjustment is
recommended.1,22,29,31,36 This is often accomplished by first categorizing
covariates, and then performing a given randomization scheme (e.g., complete
randomization, random allocation, permuted block) within each stratum. In so
doing, balance is achieved not only with respect to the number of patients within
each treatment group, but also with respect to the distribution of covariates within
these groups. This covariate adjusted randomization imposes additional balance,
17

which yields greater power in detecting treatment effects, serves to protect against
model misspecification, and ensures greater power for subgroup and interim
analyses.22,25,35,38

2.3 The Impact of Failing to Adjust for Covariates in Analysis
It has been shown in a superiority setting that failure to adjust for
important prognostic covariates at analysis leads to biased estimates of the
treatment effect, the direction and magnitude of which is dependent on the
strength of association between the covariate and outcome, as well as the level of
covariate imbalance across treatment arms.9,16,17,23,26,29,33,35,38
Robinson and Jewell33 show that in a linear setting, a strong association
between covariate and outcome decreases the variance of the treatment effect in
the context of adjustment through the reduction of residual variance, whereas a
strong association between covariate and treatment increases the variance of the
treatment effect. Thus, precision is based on these competing effects. As for
logistic regression, both a strong association between covariate and outcome and a
strong association between covariate and treatment result in increased variance
given adjustment.33 Therefore, in logistic regression, there is always an automatic
loss in precision when we adjust for covariates, regardless of whether or not they
are predictive of outcome.26 Thus, the standard error of the treatment effect in an
unadjusted analysis will be deflated as compared to the standard error in the
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adjusted analysis. However, it is important to note that this bias in the standard
error of the estimate of the treatment effect is coupled with a bias in the treatment
estimate itself.33
Gail et al.17 illustrate the nature of this bias in the treatment estimate via
Taylor series approximation in a nonlinear setting. In a linear setting, the
treatment effects in an adjusted versus an unadjusted model are equivalent. In the
nonlinear setting (i.e., in the context of logistic regression), they quantify the
discrepancy between the unadjusted treatment effect estimate and the adjusted
treatment effect estimate as:
∗

𝛽𝑡𝑟𝑡 − 𝛽𝑡𝑟𝑡

1 2 2 ℎ′′ (𝛽𝑡𝑟𝑡, ) ℎ′′ (𝛽0 )
= 𝛽𝑐𝑜𝑣 𝜎𝑐𝑜𝑣 [ ′
− ′
]
2
ℎ (𝛽𝑡𝑟𝑡 )
ℎ (𝛽0 )

where 𝛽𝑡𝑟𝑡 ∗ is the treatment effect when the covariate is not included, 𝛽𝑡𝑟𝑡 is the
2
treatment effect when the covariate is included, 𝛽𝑐𝑜𝑣 is the covariate effect, 𝜎𝑐𝑜𝑣
is
exp(𝜂)

the variance of the covariate, ℎ(𝜂) = 1+exp(𝜂), 𝜂 = 𝛽0 + 𝛽𝑡𝑟𝑡 (𝑇𝑟𝑡) + 𝛽𝑐𝑜𝑣 (𝐶𝑜𝑣),
and 𝛽0 is the intercept. They demonstrate that this discrepancy is nonzero (i.e., the
unadjusted effect will always be biased) except when there is no treatment effect,
when there is no association between covariate and outcome, or when the
variance of the covariate is zero. Furthermore, Gail et al.17 show that the bias
tends to be such that the unadjusted effect will underestimate the adjusted effect if
the treatment effect is positive, and this outweighs any benefit in standard error.
Thus, the overall result is a decrease in power when failing to adjust, and this
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effect holds even when important prognostic covariates are perfectly balanced.3,1517,26,33

In addition to the strength of association between covariate and outcome
and covariate and treatment, the marginal distribution of the treatment itself also
plays a role in the variance of the treatment estimate in logistic regression such
that the highest variance is achieved when the probability of success is 0.5. For
this reason, the operating characteristics derived from analyses of a clinical trial
may be sensitive to assumptions regarding the probability of success in the control
arm and the minimum clinical difference.
The use of covariate adjusted randomization in the design of a clinical trial
introduces correlation between treatment and covariate. As presented by Kahan
and Morris23, in the context of superiority, the variance of the treatment difference
within a stratum, given a continuous outcome, can be found from the following
expression:
𝑣𝑎𝑟(𝑌̅1 − 𝑌̅2 ) = 𝑣𝑎𝑟(𝑌̅1 ) + 𝑣𝑎𝑟( 𝑌̅2 ) − 2𝑐𝑜𝑣(𝑌̅1 , 𝑌̅2 )
In randomization schemes that do not use covariate information, the mean
outcomes for treatment one (𝑌̅1 ) and treatment two (𝑌̅2 ) can be assumed to be
independent. Therefore, the last term would be equal to zero, and the previous
equation, given equal variance of the treatment groups, would simplify to:
𝑣𝑎𝑟(𝑌̅1 − 𝑌̅2 ) =
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2𝜎 2
𝑛

However, in the absence of this assumption of independence, the correlation
between 𝑌̅1 and 𝑌̅2 is 𝜌, and the following is applicable:
𝑣𝑎𝑟(𝑌̅1 − 𝑌̅2 ) =

2𝜎 2 2𝜌𝜎 2
2𝜎 2
−
=
(1 − 𝜌)
𝑛
𝑛
𝑛

Thus, if we were to conduct an unadjusted analysis in the context of covariate
adjusted randomization, the estimated variance of the treatment effect would be
biased upwards, leading to decreased power and type I error when the outcome is
continuous.23,29,38 The magnitude of this bias is directly associated with not only
the strength of association between covariate and outcome, but also with the
strength of association between covariate and treatment (i.e., the level of
confounding). 1,31,35
In light of all of the statistical evidence in favor of adjusted analyses, it is
currently recommended that important prognostic covariates that are included in
the randomization scheme should also be included in the final analysis in the form
of a properly specified analysis of covariance.1,22,29,31,36 Whereas failure to adjust
for covariates in the superiority setting decreases type I error and power as
described previously, failure to adjust in non-inferiority may actually increase
type I error and power, but there has only been one paper to date on this subject. 18
Thus, the impact of covariate adjustment in the context of non-inferiority is an
important issue worthy of further investigation.
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2.4 The Impact of Tests of Baseline Imbalance
Given that the impact of failing to adjust for important prognostic
covariates is dependent on both the strength of association with outcome as well
as the level of imbalance, it has become common practice among some clinical
trialists to perform statistical tests of baseline covariates, and then to adjust for
those covariates which are significantly imbalanced. Although this practice has
been condemned in the statistical literature1,31,32,35,36, it remains prevalent, the
rationale being that treatment groups should be as similar as possible for an
unbiased assessment of the treatment effect. According to Altman and Dore2, 46
of the 80 trials published in four leading medical journals in 1987 conducted tests
of baseline imbalance resulting in roughly 600 tests, of which only 24 (4%) were
significant at the 5% level Pocock et al.31 find similar trends in 2002. Twentyfour (24) out of the 50 trials that they investigated (48%) employed such tests, of
which 18 out of 299 total tests (6%) were significant. Thus, as Altman1 eloquently
states, “performing significance tests to assess baseline variables is to assess the
probably of something having occurred by chance when we know that it did occur
by chance.” As a result, this practice serves as merely a test of the process of
randomization itself. Balance is, in fact, not necessary for valid inference, but
rather concerns the precision of the treatment effect. Furthermore, the exclusion
of a highly influential covariate even if it has only a very small (statistically
insignificant) imbalance across treatment arms will influence the final analysis,
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whereas the exclusion of a highly imbalanced covariate with no association with
outcome will have no effect.1,31,36
The practice of testing for baseline imbalance also has important
implications for the type I error and power of the final analysis. Following
notation given in an explanation by Senn35 using a continuous outcome and a
single continuous covariate, an unadjusted test of treatment effect under the null
hypothesis in superiority is as follows:

𝑑𝑦
1
1
√𝜎𝑦2 (
+
𝑛𝑡𝑟𝑡 𝑛𝑐𝑜𝑛𝑡 )

≥ 𝑍𝛼

where 𝑑𝑦 is the treatment effect, 𝜎𝑦2 is the variance of the treatment effect, 𝑛𝑡𝑟𝑡

and 𝑛𝑐𝑜𝑛𝑡 are the sample sizes of the treatment and control groups respectively,
and 𝑍𝛼 is the (1-𝛼)x100% standard normal quantile. Senn derives the following
expression for the size of a test of treatment effect conditional on a covariate X:

𝛼(𝑑𝑥 ) = 𝑝 𝑍 ≥
[

𝑍𝛼
√1 − 𝜌2

𝜌𝑑𝑥

−

1
1
𝑛𝑡𝑟𝑡 + 𝑛𝑐𝑜𝑛𝑡 )]

√(1 − 𝜌2 𝜎𝑥2 (

where 𝛼(𝑑𝑥 ) is the conditional size of the test, 𝑑𝑥 is the effect of the covariate, 𝜎𝑥2
is the variance of the covariate effect, and 𝜌 is the strength of the association
between covariate and outcome.

Finally, if we let 𝑑𝑥∗ represent Senn’s

“standardized prognostic imbalance” between treatment groups (i.e., the two
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sample Z statistic comparing mean covariate values across treatment groups), this
reduces to:
𝛼(𝑑𝑥 ) = 𝑝 [𝑍 ≥

𝑍𝛼
√1 − 𝜌2

−

𝜌𝑑𝑥∗
√(1 − 𝜌2 )

]

From this, we can see that for a given strength of the covariate (𝜌), as the level of
imbalance increases the size of the test also increases in a non-linear fashion in
the superiority setting. Furthermore, when the covariate is negatively associated
with outcome, increasing levels of imbalance result in increasingly conservative
unadjusted tests.

Similarly, when both the covariate and the treatment are

positively associated with outcome, an imbalance favoring the treatment group
will increase power, the magnitude of which will increase as the strength of the
covariate increases.35 On the other hand, when a covariate is negatively associated
with outcome and the treatment effect is positive, an imbalance favoring the
treatment group will result in decreased power.8 Finally, it is important to note
that such effects on type I error and power occur prior to the cutoff for
significance (5%) of a baseline test of imbalance. Thus, not only does this
practice impact the error probabilities of the final analysis, but is also offers no
guarantee

that

the

covariate

imbalance

will

not

influence

overall

conclusions.1,3,8,29,35,36 However, this practice of testing for baseline imbalance,
much like covariate adjustment in general, has received little attention in the noninferiority setting, and thus it is a topic worthy of further investigation.
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2.5 Quantifying the Impact of Adjustment for a Given Covariate Based on
Influence and Disparity
Much of the regulatory and statistical literature agrees that covariate
adjustment should be specified a priori and that those covariates included in
randomization should also be included in the final analysis.22,36 However,
methods for identifying important covariates that are not known in advance are
lacking. While significance testing continues to be a prominent practice, an
alternative has been proposed that may not have the same impact on type I error.
As previously stated, the impact of including a given covariate in analysis
can be quantified in terms of its association with treatment and its association
with outcome. In practice, these correlations are often evaluated in isolation
despite the fact that they represent competing goals. However, the simultaneous
evaluation of these factors can reveal the optimal estimate of the treatment effect
in terms of both the point estimate itself and its precision.
At the Society for Clinical Trials Annual Scientific Sessions in 1981,
Canner6 presented such a method for the inclusion of a binary covariate given a
binary outcome and zero treatment effect, which was later included in a paper by
Beach and Meier3. They present the following condensed 2x2x2 table in which
the number in each cell can be obtained by multiplying the proportions of failure
(top expression) by the total number of subjects (bottom expression).
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Table 2.5.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate

Control
Trt

Cov=0
𝑝(1 − 𝑟2 )
𝑁(1 + 𝑟1 )/2

Cov=1
𝑝(1 + 𝑟2 )
𝑁(1 − 𝑟1 )/2

𝑝(1 − 𝑟1 𝑟2 )
𝑁

𝑝(1 − 𝑟2 )
𝑁(1 − 𝑟1 )/2

𝑝(1 + 𝑟2 )
𝑁(1 + 𝑟1 )/2

𝑝(1 + 𝑟1 𝑟2 )
𝑁

𝑝(1 − 𝑟2 )
𝑁

𝑝(1 + 𝑟2 )
𝑁

𝑝
2𝑁

where 𝑁 is the number per group, 𝑝 is the proportion of failures, 𝑟1is the
correlation between treatment and covariate,and 𝑟2 can be derived as follows:
𝑟2 =

𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√𝑝(1 − 𝑝)
.
𝑝

From this, a statistic for the association between covariate and outcome (ZI),
which Canner calls “influence”, was developed in which the numerator represents
the marginal difference between the overall proportion of failures among those
with the covariate verses those without and the denominator represents its
accompanying variance.
𝑍𝐼 =

𝑝(1 + 𝑟2 ) − 𝑝(1 − 𝑟2 )
√2𝑝𝑞/𝑁

=

√2𝑁𝑝𝑟2
√𝑝𝑞

where 𝑞 = 1 − 𝑝. He similarly derives a statistic for the association between

covariate and treatment (ZD), which he refers to as “disparity”, based on the
number in the treatment group with the covariate minus the number in the
treatment group without the covariate.
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𝑁
𝑁
[( 2 ) (1 + 𝑟1 ) − ( 2 )(1 − 𝑟1 )] √2𝑁
𝑍𝐷 =
√𝑁 2

Finally, he combines these to produce a joint statistic (ZU) which gives equal
weight to disparity and influence.3,6
𝑍𝑈 =

𝑍𝐼 𝑍𝐷
√2𝑁

=

𝑝(1 + 𝑟1 𝑟2 ) − 𝑝(1 − 𝑟1 𝑟2 )
√2𝑝𝑞/𝑁

=

√2𝑁𝑝𝑟1 𝑟2
√𝑝𝑞

This ZU represents the importance of adjustment for a given covariate, and when
calculated for all candidate covariates in a dataset and ranked, it can be used to
evaluate their relative importance. While this joint statistic is of great theoretical
importance, it suffers from the impractical assumption that there is no association
between treatment and outcome (i.e., the adjusted statistic, ZA, is equal to zero). In
order to accommodate non-zero treatment effect, a third layer of correlation must
be added. Beach and Meier3 provide this extension in the context of continuous
outcome in terms of regression parameters, which Canner7 later presents via
correlation.
𝑍𝐴 =

𝑏𝑦1.2

=

̂
√𝑣𝑎𝑟𝑏
𝑦1.2

𝑟𝑦1.2 √𝑁 − 3
2
√1 − 𝑟𝑦1.2

where 𝑏𝑦1.2 is the partial regression coefficient for outcome (𝑌) and treatment
(𝑋1) given covariate (𝑋2) and 𝑟𝑦1.2 is the partial correlation coefficient for
outcome and treatment given covariate. This can be expanded as follows:
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𝑍𝐴 =

(𝑟𝑦1 − 𝑟𝑦2 𝑟12 √𝑁 − 3)
2
2
2
− 𝑟𝑦2
− 𝑟12
+ 2𝑟𝑦1 𝑟𝑦2 𝑟12
√1 − 𝑟𝑦1

given the well- known relationship
𝑟𝑦1.2 =

𝑟𝑦1 − 𝑟𝑦2 𝑟12
2
2
)(1 − 𝑟12
)
√(1 − 𝑟𝑦2

where 𝑟𝑦1 is the correlation between outcome and treatment, 𝑟𝑦2 is the correlation
between outcome and covariate, and 𝑟12 is the correlation between treatment and
outcome. If we subtract 𝑍𝐴 from 𝑍𝑈 , we can obtain a value for the importance of
adjustment controlling for the treatment effect.7
These methods are sufficient to fully quantify the impact of adjustment for
a single covariate or multiple covariates given that they are independent of each
other. However, in a real trial setting, a strictly additive model is rarely sufficient.
Although theoretical evaluations of this scenario become increasingly impractical
as the number of important covariates increases, Berger4 proposes an alternate
method for the evaluation of disparity in which the first covariate is selected in the
usual way, but subsequent covariates are conditioned such that the adjusted
discrepancy is the weighted average of the disparity in each of the strata formed
by the existing covariates.
The impact on type I error of these data driven methods for covariate
selection is not well understood even in the context of superiority as they have not
been well adopted by the clinical trials community. In non-inferiority, it has been
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shown that failure to include important covariates increases type I error.18,27 Thus,
these methods are worth further evaluation. The following three chapters consist
of three original papers designed to build upon previous research in the areas of
covariate adjustment at randomization and analysis, methods for covariate
selection when prognostic factors are not known a priori, and practical
application in accordance with the three aims as previously stated.
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Chapter 3
Aim 1:
The Impact of Covariate Adjustment at Randomization and
Analysis for Binary Outcomes: Understanding Differences
Between Superiority and Non-Inferiority Trials

The question of when to adjust for important prognostic covariates often
arises in the design of clinical trials, and there remain various opinions on whether
to adjust during both randomization and analysis, at randomization alone, or at
analysis alone.

Furthermore, little is known about the impact of covariate

adjustment in the context of non-inferiority designs. The current simulationbased research explores this issue in the non-inferiority setting, as compared to
the typical superiority setting, by assessing the differential impact on power, type
I error, and bias in the treatment estimate as well as its standard error, in the
context of logistic regression under both complete and covariate adjusted
permuted block randomization algorithms.
In both the superiority and non-inferiority settings, failure to adjust for
covariates that influence outcome in the analysis phase, regardless of prior
30

adjustment at randomization, results in treatment estimates that are biased toward
zero, with standard errors that are deflated. However, as no treatment difference
is approached under the null hypothesis in superiority and under the alternative in
non-inferiority, this results in decreased power and nominal or conservative
(deflated) type I error in the context of superiority, but inflated power and type I
error under non-inferiority.

Results from the simulation study suggest that,

regardless of the use of the covariate in randomization, it is appropriate to adjust
for important prognostic covariates in analysis, as this yields nearly unbiased
estimates of treatment as well as nominal type I error.

3.1 Introduction
The non-inferiority trial design is growing progressively more popular as
the need for comparable therapies with secondary advantages increases. The
challenges that arise in the design and analysis of such a trial have been discussed
in the FDA Guidance on non-inferiority trials41 as well as methodological
research on proper specification of hypotheses, the choice of active control,
determination of the non-inferiority margin, and the appropriate analysis
method.5,11-13,18,22 However, critical gaps in the literature remain regarding key
design issues, specifically the impact of covariate adjustment at both
randomization and at the analysis phase.
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In a PubMed search of phase-III clinical trials published in the last ten
years containing the word “non-inferiority”, 44.8% of 58 trials utilized complete
randomization

and

unadjusted

primary

analyses.

Covariate

adjusted

randomization and appropriate analysis of covariance or stratification was used in
20.7% of trials. Covariate adjustment at randomization, but not at analysis was
done in 25.7%, and adjustment at analysis but not at randomization was done in
8.6% of the trials.

This review of current practice shows that there is still

considerable variability in the way that clinical trialists use covariate information,
a finding that is not surprising considering the lack of attention it has received in
the non-inferiority literature.
This chapter expands the research on covariate adjustment in the noninferiority setting by examining the impact of adjustment at randomization as well
as at analysis using logistic regression models. A simulation study is conducted to
examine the operating characteristics in both superiority and non-inferiority
settings.

Section 1.2 reviews the existing statistical literature on covariate

adjustment. Sections 1.3 and 1.4 present the simulation methods and results, and
Section 1.5 discusses the differential impact of covariate adjustment in these two
settings.
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3.2 Existing Literature
Little work has been published to date to examine the impact of covariate
adjustment at both randomization and analysis in the context of non-inferiority
trials. Garrett18 explains that, due to the reversal of hypotheses from the
superiority setting, there is also a reversal of the impact of errors. Thus, he
cautions readers that the power and type I error is inflated when important
prognostic factors are ignored in the non-inferiority setting. However, this work
does not take into account the potential impact of the randomization scheme.
It has been shown in a superiority setting that failure to adjust for
important prognostic covariates at either randomization or analysis leads to biased
estimates of the treatment effect, the direction and magnitude of which is
dependent on the strength of association between the covariate and outcome, as
well as the level of covariate imbalance across treatment arms.9,16,17,23,26,29,33,35,38
Gail et al.17 illustrate the nature of this bias via Taylor series approximation in a
nonlinear setting. They show that in a linear setting, the estimated treatment
effect in an adjusted versus in an unadjusted model are equivalent.

In the

nonlinear (i.e., the logistic) setting, they quantify the discrepancy between the
adjusted treatment effect estimate and the unadjusted treatment effect estimate
and demonstrate that this discrepancy is nonzero (i.e., the unadjusted effect will
always be biased) except when there is no treatment effect, when there is no
association between covariate and outcome, or when the variance of the covariate
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is zero. Furthermore, Gail et al. show that the bias tends to be such that the
unadjusted effect will underestimate the adjusted effect if the treatment effect is
positive, resulting in a decrease in power, and that this effect holds even when
covariates are perfectly balanced.

As Robinson and Jewell33 point out, this

underestimation of the treatment effect when failing to adjust for covariates
outweighs any benefit in standard error.3,15,16,17,26,33
The impact of covariate adjustment at randomization has been evaluated in
the context of superiority. Kahan and Morris23 illustrate that, for continuous,
binary, and time-to-event outcomes, stratified randomization creates correlation
between treatment arms.

Thus, unadjusted analyses in this context result in

decreased power and type I error, as well as inflated standard errors of the
treatment effect.
In light of the statistical evidence in favor of adjusted analyses, it is clear
that important prognostic covariates that are included in the randomization
scheme should also be included in the final analysis in the form of a properly
specified analysis of covariance,22,29,36 and, in fact, this results in unbiased
estimates of treatment effect, as well as nominal power and type I error.
However, the full impact of covariate adjustment in the non-inferiority setting
remains to be demonstrated and is a topic worthy of further investigation.
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3.3 Simulation Studies
Parameters are specified according to both the hypothesis of interest (null
or alternative) and the scenario of interest (superiority or non-inferiority). Four
simulation studies were designed to perform complete randomization and
covariate adjusted permuted block randomization in the context of superiority and
non-inferiority designs. All simulations conducted both unadjusted and adjusted
analyses based on the following models:
𝜋
) = 𝛽0 + 𝛽1 𝑇𝑟𝑡
1−𝜋

𝑈𝑛𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑: ln (
𝜋

𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑: ln (1−𝜋) = 𝛽0 + 𝛽1 𝑇𝑟𝑡 + 𝛽2 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒
The probability of success in the control group (𝜋𝐶 ) was set at 80%. This value
was chosen based on a non-inferiority setting where the active control may have a
high probability of success however the experimental treatment offers other
advantages such as fewer side effects.

3.3a Simulation Parameters
The probability of success in the treatment group (𝜋𝑇 ), the sample size,
and the pre-determined margin were differentially specified depending on the
statistical hypothesis to be tested (superiority or non-inferiority), but the
simulation strategy remained the same. For the superiority setting, the probability
of success in the treatment group was set at 90% in order to mimic a trial with an
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expected absolute difference in treatment of 10%.

The null hypothesis is

𝐻0 : 𝜋𝐶 = 𝜋𝑇 = 0.80, and the alternative is 𝜋𝐶 = 0.80 and 𝜋𝑇 = 0.90. Thus, 𝛽1
is estimated to be ln(1) = 0 under the null hypothesis and ln(2.25) = 0.811
under the alternative. This information was then used to calculate the total sample
size of 𝑁 = 392 subjects in order to ensure power of 80% when there was no
effect of the covariate (𝛽2 = 0).
The value of 𝛽2was allowed to vary from -3.0 to 3.0 in increments of 0.5
in order to evaluate the effect of strength of covariate on operating characteristics,
and equations (1) and (2) above were used to derive the intercept, 𝛽0, for each
scenario. Although it is not expected that any covariate would have a coefficient
as high as 3.0, this range was included in the simulation to examine the theoretical
setting.
For the case of non-inferiority, we set the non-inferiority margin at 0.10,
resulting in the following hypotheses:
𝐻0 : 𝜋𝐶 − 𝜋𝑇 ≥ 0.10
𝐻1 : 𝜋𝐶 − 𝜋𝑇 < 0.10
where 𝜋𝐶 = 0.80 and 𝜋𝑇 = 0.70 under the null and 𝜋𝐶 = 𝜋𝑇 = 0.80 under the
alternative. This yielded a 𝛽1under the null of -0.539 and under the alternative a
value of zero. An odds ratio of 0.583 was derived from the expected probability of
success in each of the two groups, which served as the cutoff for claiming noninferiority. The values of 𝛽2 and 𝛽0 remained similar to the superiority setting.
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The total sample size was estimated as 𝑁=676, so that the power to detect a
treatment difference when 𝛽2 = 0 was again 80%.
It should be noted that results on the linear/risk difference scale are not
necessarily immediately applicable to the logistic/odds ratio scale but may require
translation. The authors present hypotheses and parameters in terms of the linear
scale to facilitate communication with clinical investigators but then analyze
results using logistic regression to avoid convergence issues that would otherwise
arise in the tails of the nonlinear distribution.26 It is also noteworthy that sample
size has to be increased slightly when the effect size is translated from a risk
difference to an odds ratio.20

3.3b Simulation Strategy
The simulated subject dataset is filled sequentially by first assigning the
level of covariate (0 or 1), based on dichotomization of a random uniform
distribution, and then a treatment indicator via either complete randomization,
where the probability that the ith patient is assigned to treatment (pi,trt) is 0.5, or
permuted block randomization within each level of the covariate according to the
following:

𝑝𝑖,𝑡𝑟𝑡 =

(𝑖
(𝑏⁄2) (1 + 𝑖𝑛𝑡 ( − 1)⁄𝑏)) − 𝑛𝑖−1,𝑡𝑟𝑡
(𝑖
𝑏 (1 − 𝑖𝑛𝑡 ( − 1)⁄𝑏)) − (𝑖 − 1)
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where i = subject, b = block size, int = next highest integer value, and ni-1 =
number previously assigned to treatment. A block size of six was chosen as a
compromise between the authors’ beliefs about current popular practice and the
desire for results to be comparable to those of Kahan and Morris23, who used a
block size of eight. The probability of success for each patient is assigned as
follows:
𝑝𝑖,

𝑠𝑢𝑐𝑐𝑒𝑠𝑠

=

exp(𝛽1 𝑇𝑟𝑡 + 𝛽2 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒)
1 + exp(𝛽1 𝑇𝑟𝑡 + 𝛽2 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒)

and again compared to a random uniform distribution for dichotomization. Once
the subject table is populated, unadjusted and adjusted analyses are conducted,
and estimates of the odds ratios of the treatment effect, as well as their standard
errors and two-sided 95% confidence intervals are extracted.
Power, defined as the percentage of trials under the alternative hypothesis
in which the lower bound of the confidence interval for the odds ratio crosses the
pre-determined margin (>1.0 for superiority or >0.583 for non-inferiority), as well
as type I error, defined as the percentage of trials under the null in which the
lower bound of the confidence interval for the odds ratio crosses the predetermined margin, are calculated across 10,000 iterations. Bias in the estimate
of the treatment effect, defined as the average difference between the estimate and
the true value of 𝛽1, and bias in the standard error of the estimate of treatment
effect, defined as the mean difference between empirical and model standard
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errors, are calculated under the alternative hypothesis in the context of superiority
and under the null hypothesis in the context of non-inferiority, as this is where
one would expect to find a treatment difference.

3.4 Simulation Results
3.4a Superiority
In the context of superiority, there is a slight loss in power as 𝛽2 (which
represents the strength of the covariate) moves away from zero in either direction
for unadjusted analyses and a slight gain in power for adjusted analyses.
Furthermore, there appears to be little impact of balancing at randomization
among adjusted analyses, but some improvement of covariate adjusted permuted
block randomization over complete randomization among unadjusted analyses.
Type I error, under all scenarios, yields close to nominal values regardless of the
value for 𝛽2 , with the exception of the scenario that employed covariate adjusted
permuted block randomization coupled with an unadjusted analysis.

In this

scenario, type I error decreased as 𝛽2 moved away from zero in either direction.
Under the alternative hypothesis, we can see that the unadjusted analyses’
treatment effects and standard errors underestimate those of the adjusted analyses.
Furthermore, the bias in the standard error appears to be less severe for covariate
adjusted permuted block randomization than for complete randomization due to
the correlation it creates between treatment groups.
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However, the treatment

estimate, as well as its accompanying standard error, is nearly unbiased (a slight
positive bias was detected, but determined to be minimal) in adjusted analyses,
with negligible effect of covariate balancing at randomization.

Figure 1: Superiority
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Figure 3.4a.1 Operating Characteristics for Covariate Adjustment in Superiority
Trials

3.4b Non-Inferiority
The operating characteristics in the context of non-inferiority are quite
different from superiority. In this setting, power decreases slightly as 𝛽2 moves
away from zero in either direction for adjusted analyses, and type I error is nearly
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maintained regardless of covariate balancing at randomization via permuted
block. For unadjusted analyses, an opposite effect from that demonstrated in the
context of unadjusted analyses in superiority is observed. Power and type I error
is increased as 𝛽2 moves away from zero in either direction. This increase in
type I error for unadjusted analyses in the presence of an influential prognostic
covariate is greater in complete randomization than in the context of covariate
adjusted permuted block randomization. Type I error rates are nearly maintained
for adjusted analyses regardless of balancing at randomization.
The treatment estimate and its standard error are unbiased for adjusted
analyses, whereas the treatment estimate is biased upward toward zero for
unadjusted analyses regardless of balancing at randomization via permuted block.
The standard error of this estimate follows the same pattern as the alternative
hypothesis in the superiority setting (namely, standard errors are deflated for
unadjusted analyses with covariate adjusted permuted block randomization
yielding a less pronounced effect).
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Figure 2: Non-Inferiority
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Figure 3.4b.1 Operating Characteristics for Covariate Adjustment in NonInferiority Trials

3.5 Discussion
The results presented above demonstrate that adjustment for important
prognostic covariates in analysis is always preferred, regardless of whether the
hypothesis to be tested is one of superiority or non-inferiority. In a superiority
setting, adjusted analyses yield greater power to detect a treatment difference as
compared to unadjusted analyses, as well as nominal type I error. In a noninferiority setting, adjusted analyses do not have the added benefit of increased
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power but are protective against unacceptable increases in type I error.
Furthermore, adjusted analyses yield nearly unbiased estimates of treatment effect
in both scenarios and biases in standard error that seem unavoidable given the
nature of the nonlinear relationship between outcome and predictors.
These findings expand upon those of Garrett18 by further quantifying the
impact of failure to adjust for important prognostic covariates in terms of bias in
the treatment estimate and subsequent implications for power and type I error. It
also provides noteworthy extensions in terms of the evaluation of different
covariate adjustment strategies (i.e., randomization versus analysis), a direct
comparison with a superiority design, and the extendibility of such findings to
different specifications of parameters. For example, in addition to the strength of
association between covariate and outcome, the probability of success in the
control also plays a role in the variance of the treatment estimate such that
different starting points do not translate to equivalent odds ratios. Thus, an
absolute non-inferiority margin of 0.10, which we set in the non-inferiority
setting, does not always translate to a relative non-inferiority margin of 0.583, but
only given an assumed probability of success in the control of 80%.

To

demonstrate the sensitivity of findings, a second simulation was undertaken in
which the absolute non-inferiority margin remained 0.10, but the probabilities of
success were changed to 𝜋𝐶 = 0.55 and 𝜋𝑇 = 0.45 (which translates to a relative
non-inferiority margin of 0.669). In this scenario, the overall variability is
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increased and the impact of failure to adjust for covariates is magnified, but
similar trends were observed in all operating characteristics for the non-inferiority
setting.
A limitation of this work lies in the fact that the observed differences
between unadjusted and adjusted analyses can be thought of in terms of model
inconsistency. The adjusted model is a conditional, or subject specific model,
whereas the unadjusted model is a marginal, or population averaged, model.
Thus, one could argue that the bias illustrated in the unadjusted treatment effect
estimates is actually just a result of the difference between the two modeling
strategies.24,37 While this is worth comment, the simulation results, as presented,
retain their practical value as an explanation of the impact of covariate
adjustment.
Finally, the current research suggests that, in the context of adjusted
analyses of binary outcomes, covariate adjusted permuted block randomization
may not provide much gain over complete randomization. In fact, there were
only minimal effects of balancing at randomization in the context of adjusted
analyses for any of the operating characteristics that were presented, a result that
was maintained even under a scenario in which a significant 70/30 covariate
imbalance was forced (simulation not shown). In addition, the use of covariate
adjusted permuted block randomization results in a loss of randomness via an
increase in the number of deterministic assignments.44 However, further research
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is required to determine whether these findings can be generalized to other
randomization schemes.
This research illustrates the impact of covariate adjustment at
randomization and analysis in non-inferiority trials with binary outcomes and
demonstrates the importance of conducting adjusted analyses in the presence of
important prognostic covariates. Although we have exaggerated the covariate
effect (i.e., 𝛽2), this was done for purely theoretical purposes. In practice, it is
unlikely that one would see a covariate effect of +/- 3.0 and the resulting type I
error rate of 0.175. Regardless, our results hold as we see an inflation in the type I
error when the covariate is not equal to 0; for example, a more practical case of a
covariate effect of +/- 1.5 shows a type I error rate of 0.045. This suggests that
proper adjustment will result in unbiased estimates of treatment and reduce the
probability of committing a type I error, which is of particular importance in noninferiority trials, as claiming non-inferiority when it is false may have severe
implications for patients.
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Chapter 4
Aim 2:
Choosing Covariates for Adjustment in Non-Inferiority Trials
with Binary Outcomes Based on Influence and Disparity
It has been shown that the type I error rate is inflated when important
covariates are excluded from a non-inferiority analysis.18,27 Traditionally, whether
to adjust for a covariate in a model is based solely on statistical significance or
some other criteria such as Akaike information criterion (AIC) that relates to the
magnitude of the effect on outcome. In addition, some select based on tests of
baseline imbalance. However, several authors suggest that these aspects be
considered simultaneously. Canner6 developed a statistic for binary outcomes to
determine the relative importance of including a covariate in a model based on
both its effect on outcome and its association with treatment. Although Canner’s
approach assumed no treatment effect, Beach and Meier3 extended this to nonzero treatment effects in the context of linear regression. The current research
combines the methods of Canner for binary outcomes with the methods of Beach
and Meier for non-zero treatment effect in order to quantify the relative
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importance of including covariates in a non-inferiority study with a binary
outcome. Theoretical results are presented and applied via simulation.

4.1 Introduction
In observational studies, the goal of covariate adjustment is often to
quantify the impact of various baseline factors on outcome in order to understand
the predictors of disease. In large randomized clinical trials, the goal becomes the
unbiased and precise estimation of a treatment’s effect on outcome. A truly
unbiased estimate of treatment effect results from adjustment for any covariate
with even a slight impact on outcome. As this is, of course, impossible in
practice, a method of choosing the most important subset of potential covariates is
of value.
If the goal is to obtain an accurate and unbiased estimate of the treatment
effect, then one should choose a subset of covariates based on their association
with outcome. This can be done via tests of bivariate association in which any
covariate reaching statistical significance is included in the model for outcome.
Alternatively, stepwise selection procedures which consider the iterative addition
or removal of a single, or subset, of covariates can be employed, and decisions
can be based on p-values, AIC, or some other criteria of influence. For binary
outcomes, accuracy and precision represent competing goals; as the number of
covariates in the model increases, the accuracy of the point estimate will also
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increase, but the precision will decrease given the non-linear nature of the
relationship with outcome.
If precision of the treatment estimate is the goal, then one should choose
covariates based on the disparity with treatment allocation rather than association
with outcome. Some trialists do not consider this issue in the formation of the
model, but rather trust that the randomization scheme has controlled for any
chance imbalances.1 Others choose to test this formally with two-sample tests for
baseline imbalance and then adjust for those covariates reaching statistical
significance. While this practice has been condemned in much of the regulatory
and statistical literature due to its impact on type I error, 22,36 it remains popular
and is often reported in the first table of many manuscripts.
Perhaps, a better approach for choosing covariates would consider both
influence on outcome and disparity with treatment. In a presentation to the
Society for Clinical Trials in 1981, Canner6 developed a statistic to do this
simultaneously for binary outcomes with no treatment effect, which Beach and
Meier3 later extended for continuous outcomes with non-zero treatment effect.
The current research seeks to expand Canner and Beach and Meier’s work for
application to a non-inferiority design with a binary outcome.
A typical superiority design generally seeks to show that a new drug is
superior to placebo by some predetermined amount. A non-inferiority study,
however, is often used when previous studies have established superiority of a
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therapy, but a new therapy may offer some additional benefit such as lower cost,
greater ease of administration, or fewer side effects. In this case, if the new drug is
equally, or even slightly less, efficacious than the current standard of care, it
would likely be of clinical benefit. Thus, the non-inferiority design seeks to
answer the question of “no worse than” by some amount, the non-inferiority
margin (𝑑), that would be deemed an acceptable loss given the benefit tradeoff.
This reversal of hypotheses leads to a reversal in the implications of type I and
type II error.5 As such, biased and imprecise estimates of treatment effect in noninferiority studies can increase the likelihood of rejecting the null hypothesis and
claiming non-inferiority. Thus, there is often a non-trivial inflation of the type I
error probability when analyses fail to account for important covariates.18,27
Given this important difference, there is potential for an extension of Canner and
Beach and Meier’s joint statistic for influence and disparity for use in
identification of important covariates requiring adjustment in non-inferiority
trials. Section 4.2 reviews the existing literature.

Section 4.3 presents a

theoretical argument for the inclusion of the non-inferiority margin in the statistic,
followed by a simulation study in Sections 4.4 through 4.6, advice for practical
use in Section 4.7, and discussion in Section 4.8 .
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4.2 Existing Literature
Canner6 presented a method to quantify the impact of adjustment for a
binary covariate given a binary outcome and no treatment effect that was based on
both disparity (i.e., imbalance between treatment arms) and influence on outcome.
In 1989, Beach and Meier3 expanded upon Canner’s result to include a non-zero
treatment effect. They presented the following condensed 2x2x2 table, in which
the columns corresponding to the number of successes for each combination of
treatment and covariate have been removed.
Let 𝑁 be the number per treatment arm, 𝑝 be the overall proportion of
failure, and 𝑟1be the correlation between treatment (𝑋1) and covariate (𝑋2). 𝑟2
quantifies the strength of the association between covariate (𝑋2) and outcome (𝑌)
and can be derived as follows:
𝑟2 =

𝑐𝑜𝑟𝑟(𝑋2 , 𝑌)√𝑝(1 − 𝑝)
𝑝

The number in each cell of Table 4.2.1 can be obtained by multiplying the
proportion of failures (first expression) by the total number of individuals (second
expression). Thus, for the first cell, which represents the number without the
covariate in the control arm, there are 𝑝(1 − 𝑟2 ) ∗ 𝑁(1 + 𝑟1 )/2 individuals.
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Table 4.2.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate

Control
Arm
Treatment
Arm

Without
Covariate
𝑝(1 − 𝑟2 )
𝑁(1 + 𝑟1 )/2

With
Covariate
𝑝(1 + 𝑟2 )
𝑁(1 − 𝑟1 )/2

𝑝(1 − 𝑟2 )
𝑁(1 − 𝑟1 )/2

𝑝(1 + 𝑟2 )
𝑁(1 + 𝑟1 )/2

𝑝(1 + 𝑟1 𝑟2 )
𝑁

𝑝(1 − 𝑟2 )
𝑁

𝑝(1 + 𝑟2 )
𝑁

𝑝
2𝑁

Total

Total
𝑝(1 − 𝑟1 𝑟2 )
𝑁

From this, Canner developed an “influence” statistic for the distribution of
covariate across outcome (𝑍𝐼 ) and a “disparity” statistic for the distribution of
covariate across treatment arms (𝑍𝐷 ):
𝑍𝐼 =

𝑍𝐷 =

𝑝(1 + 𝑟2 ) − 𝑝(1 − 𝑟2 )
√2𝑝𝑞/𝑁

=

√2𝑁𝑝𝑟2
√𝑝𝑞

𝑁
𝑁
[( 2 ) (1 + 𝑟1 ) − ( 2 ) (1 − 𝑟1 )] √2𝑁
√𝑁 2

= √2𝑁𝑟1

where 𝑞 = 1 − 𝑝. The statistic for the unadjusted treatment effect (𝑍𝑈 ) is:
𝑍𝑈 =

𝑝(1 + 𝑟1 𝑟2 ) − 𝑝(1 − 𝑟1 𝑟2 )
√2𝑝𝑞/𝑁

=

√2𝑁𝑝𝑟1 𝑟2
√𝑝𝑞

and the adjusted treatment effect is equal to zero (𝑍𝐴 = 0) by construction
because the treatment effect is equal to zero. Thus, it follows that the difference
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between the unadjusted and adjusted statistics is the product of the statistics for
influence and disparity:

𝑍𝑈 − 𝑍𝐴 = 𝑍𝑈 =

√2𝑁𝑝𝑟1 𝑟2
√𝑝𝑞

(
=

√2𝑁𝑝𝑟2
) √2𝑁𝑟1
√𝑝𝑞
√2𝑁

=

𝑍𝐼 𝑍𝐷
√2𝑁

This result can fully quantify the impact of failing to adjust for a covariate when
there is no treatment effect. However, when a treatment effect is present, 𝑍𝐴 is no
longer equal to zero. Beach and Meier extended Canner’s method to present
similar findings for a non-zero treatment effect in the context of linear regression
parameters, which Canner7 then re-derived in terms of correlations.
Canner presented the adjusted treatment effect as:
𝑍𝐴 =

𝑏𝑦1.2

=

̂
√𝑣𝑎𝑟𝑏
𝑦1.2

𝑟𝑦1.2 √𝑁 − 3
2
√1 − 𝑟𝑦1.2

where 𝑏𝑦1.2 is the partial regression coefficient for outcome (𝑌) and treatment
(𝑋1) given covariate (𝑋2) and 𝑟𝑦1.2 is the partial correlation coefficient for
outcome (𝑌) and treatment (𝑋1) given covariate (𝑋2). It can also be shown that:
𝑍𝐴 =

(𝑟𝑦1 − 𝑟𝑦2 𝑟12 √𝑁 − 3)
2
2
2
− 𝑟𝑦2
− 𝑟12
+ 2𝑟𝑦1 𝑟𝑦2 𝑟12
√1 − 𝑟𝑦1

given the well-known relationship:
𝑟𝑦1.2 =

𝑟𝑦1 − 𝑟𝑦2 𝑟12
2
2
)(1 − 𝑟12
)
√(1 − 𝑟𝑦2
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where 𝑟𝑦1 is the correlation between outcome (𝑌) and treatment (𝑋1), 𝑟𝑦2 is the
correlation between outcome (𝑌) and covariate (𝑋2), and 𝑟12 is the correlation
between treatment (𝑋1) and covariate (𝑋2). This expression for 𝑍𝐴 can be used in
conjunction with previous results to evaluate the impact of adjustment for a
covariate when the treatment effect is non-zero.

4.3 Extension to Non-Inferiority Setting
The notation and results of Canner6,7 and Beach and Meier3 can be
extended to develop an expression for the impact of adjustment for a covariate in
the non-inferiority setting. In this scenario, the assumed treatment effect is nonzero and equal to the non-inferiority margin (𝑑). The condensed 2x2x2 table can
be written as:

Table 4.3.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate with
Treatment Effect Equal to Non-Inferiority Margin (𝑑)
Without Covariate

With Covariate

Total

Control
Arm

𝑝(1 − 𝑟2 )
𝑁(1 + 𝑟1 )/2

𝑝(1 + 𝑟2 )
𝑁(1 − 𝑟1 )/2

𝑝(1 − 𝑟1 𝑟2 )
𝑁

Treatment
Arm

(𝑝 + 𝑑)(1 − 𝑟2 )
𝑁(1 − 𝑟1 )/2

(𝑝 + 𝑑)(1 + 𝑟2 )
𝑁(1 + 𝑟1 )/2

(𝑝 + 𝑑)(1 + 𝑟1 𝑟2 )
𝑁

Total

(1/2)(2𝑝 + 𝑑(1 − 𝑟1 ))(1 − 𝑟2 )
𝑁

(1/2)(2𝑝 + 𝑑(1 + 𝑟1 ))(1 + 𝑟2 )
𝑁

(1/2)(2𝑝 + 𝑑(1 + 𝑟1 𝑟2 ))
2𝑁
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In this case, the new expression for the association between covariate and
outcome is:
𝑟2∗ =

2𝑝 + 𝑑
2𝑝 + 𝑑
2 (1 − 2 )
2𝑝 + 𝑑
2

𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√

From this, a new expression for influence (𝑍𝐼∗ ) is derived from the marginals as
before:
1
1
( ) (2𝑝 + 𝑑(1 + 𝑟1 ))(1 + 𝑟2∗ ) − ( ) (2𝑝 + 𝑑(1 − 𝑟1 ))(1 − 𝑟2∗ )
2
2
𝑍𝐼∗ =
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁
𝑍𝐼∗ =

2𝑝𝑟2∗ + 𝑑(𝑟1 + 𝑟2∗ )
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁

Canner’s unadjusted statistic can then be re-written to include this:
𝑍𝐶 ∗ =

𝑍𝐼∗ 𝑍𝐷
√2𝑁

and combined with the adjusted statistic as follows:
𝑍𝐶 ∗ − 𝑍𝐴 =

𝑍𝐼∗ 𝑍𝐷
√2𝑁

−

(𝑟𝑦1 − 𝑟𝑦2 𝑟12 )√2𝑁 − 3)
2
2
2
− 𝑟𝑦2
− 𝑟12
+ 2𝑟𝑦1 𝑟𝑦2 𝑟12
√1 − 𝑟𝑦1

where the correlation between outcome and treatment (𝑟𝑦1 ), the correlation
between outcome and covariate (𝑟𝑦2 ), and the correlation between treatment and
covariate (𝑟12 ) are now equal to28:
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𝑟𝑦1 =

𝑟𝑦2

1
1
𝑝𝑟1 𝑟2∗ + ( ) 𝑑 + ( ) 𝑑𝑟1 𝑟2∗
2
2
√𝑝 + (1) 𝑑 + (1) 𝑑𝑟1 𝑟2∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1 𝑟2∗ − (1) 𝑑 2 − (1) 𝑑 2 𝑟`1 𝑟2∗ − (1) 𝑑 2 𝑟12 𝑟2∗ 2
2
2
4
2
4

1
1
( ) 𝑑𝑟1 + ( ) 𝑑𝑟2∗ + 𝑝𝑟2∗
2
2
=
1
1
√𝑝 + ( ) 𝑑 + ( ) 𝑑𝑟1 𝑟2∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1 𝑟2∗ − (1) 𝑑 2 − (1) 𝑑 2 𝑟1 𝑟2∗ − (1)𝑑 2 𝑟12 𝑟2∗ 2
2
2
4
2
4

𝑟12 = 𝑟1
This new statistic (𝑍𝐶 ∗ − 𝑍𝐴 ) can be used to evaluate the importance of
adjustment for one covariate over another in a non-inferiority setting.

4.4 Relative Importance of 𝒓𝟏 and 𝒓𝟐
To evaluate the impact of varying scenarios on this statistic for importance
(𝑍𝐶 ∗ − 𝑍𝐴 ) in a non-inferiority setting, a simulation study was undertaken. The
simulation explored this statistic’s behavior when subject to changes in 𝑟1 and 𝑟2
for given proportions of failure (or success) (𝑝) and non-inferiority margins (𝑑).
Figure 4.4.1 illustrates the impact of 𝑟1 and 𝑟2 when p is 0.4, d is 0.1, and 𝑟1 and 𝑟2
are varied from -0.9 to 0.9. In this scenario, 𝑁 is set to be 388 per arm to ensure
80% power.
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Figure 4.4.1 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1
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The statistic for the importance of adjustment is presented as the contour and
ranges from -20.35 to 20.30. The green represents values of the statistic close
to −𝑍𝐴 , which occur when either 𝑟1or 𝑟2 are close to zero. The point (𝑟1 , 𝑟2 ) =
(0,0) occurs at the center of both the three dimensional and contour plots. The
yellow and beige represent increasingly positive values of the statistic, which
occur when 𝑟1 and 𝑟2 are in the same direction (i.e., both positive or both
negative); blue and purple represent increasingly negative values of the statistic,
which occur when 𝑟1 and 𝑟2 are in opposite directions (i.e., one positive and one
negative). Furthermore, a near symmetry exists such that similar values of the
statistic are obtained when 𝑟1 is positive and 𝑟2 is negative as when 𝑟1 is negative
and 𝑟2 is positive, and the same is true for associations in the same direction.
We can see that according to our statistic, evaluation of either imbalance
(𝑟1) or strength of association (𝑟2 ) in isolation is not sufficient to identify the most
important subset of covariates. Rather, adjustment is necessary when a covariate
is both imbalanced and strongly associated with outcome, and these two forces
are given similar weight. We will now narrow our focus to more practical values
(i.e., where 𝑟1 and 𝑟2 range from -0.2 to 0.2) to explore the relative importance of
these two factors.
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Figure 4.4.2 ZC*-ZA for Reduced Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 =
0.1
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Given this reduced range, it becomes apparent that even for moderate strengths of
association (i.e., 𝑟1 and 𝑟2 between -0.2 and 0.2) the statistic is close to −𝑍𝐴 and
adjustment is not necessary. However, when either 𝑟1 or 𝑟2 is large and the other
is non-negligible, adjustment is necessary. Such findings are consistent with
previous research on covariate adjustment in the presence of imbalance.1,3,8,29,31,36
In addition, it is important to note that while the magnitude of the statistic
is dependent on the sample size and probability of failure, the relative importance
given to 𝑟1 and 𝑟2 remains generally consistent. For example, Figure 4.4.3 shows
the statistic when 𝑝 is 0.1 (𝑁 is set to be 199 to maintain the same power as
above). With the probability of failure in the standard of care now equal to the
treatment effect (i.e., the non-inferiority margin), the impact of the treatment
effect is more apparent. The range of the statistic is reduced and, while the shape
remains similar, the asymmetry is more pronounced.
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Figure 4.4.3 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 199, 𝑝 = 0.1, 𝑑 = 0.1
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4.5 Relationship to Bias
The proposed statistic also has an important relationship to the bias in the
estimate of the treatment effect on the risk difference scale. The bias in the
original case where 𝑝 is 0.4, 𝑑 is 0.1, and 𝑁 is 388 is presented below as the
unadjusted estimate minus the adjusted estimate (𝛽𝑢𝑛𝑎𝑑𝑗 − 𝛽𝑎𝑑𝑗 ).
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Figure 4.5.1 Bias for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1
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From the comparison of Figure 4.5.1 to Figure 4.4.1, one can see that the statistic
for importance of adjustment maps nicely to the bias in the treatment estimate.
Given 𝑟1 and 𝑟2 equal to zero, the statistic is equal to −𝑍𝐴 and the estimate of the
treatment effect is unbiased. When 𝑟1 and 𝑟2 are in the same direction (i.e., both
positive or both negative), the unadjusted estimate is biased upward, and when 𝑟1
and 𝑟2 oppose each other (i.e., one is positive and the other is negative), the
unadjusted estimate is biased downward. In the case of a two-sided test, this is an
unimportant distinction. However, in the context of non-inferiority, a one-sided
test (or confidence interval) is used, and this directionality becomes important.

4.6 Implications for Error
Adjustment for covariates will always slightly increase the width of the
confidence interval of the treatment effect in the context of logistic regression,
and the degree to which it changes is primarily dependent on the magnitude (but
not the directionality) of 𝑟1 .33 However, as shown in Figure 4.6.1, this increase
only becomes important at extreme values of 𝑟1 and 𝑟2 .
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Figure 4.6.1 Change in Width of the 95% Confidence Interval (Unadjusted –
Adjusted) for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1
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If one is concerned about whether the non-inferiority margin is crossed, as
in the case of a confidence interval approach to a non-inferiority hypothesis, both
the point estimate and its variance must be considered. As in the theoretical
schematic presented in Figure 4.6.2, while the increased variance imposed by
adjustment may push the upper bound beyond the margin, decreasing the potential
to reject the null hypothesis of inferiority, this impact is small in comparison to
the change in the estimate itself. Thus, there is a serious potential for committing
a type I error when failing to adjust for a covariate that has imbalance and
influence in the same direction, regardless of whether that direction is positive or
negative.

Fail to Reject
when Modeling
Probability of
Success
(tx inferior)

Fail to Reject
when Modeling
Probability of
Failure
(tx inferior)

Reject
(tx non-inferior)

−𝑑

𝑑

Figure 4.6.2 Movement of the 95% Confidence Interval Given Adjustment and
Implications for Error Probabilities in Non-Inferiority Trials
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4.7 Practical Use
In practice, the statistic for importance of adjustment can be used as a
diagnostic tool. To this end, one might calculate values of the statistic for all
available covariates and then rank them. The covariate corresponding to the
largest value would be the most important covariate for which to adjust and so on.
For illustrative purposes, consider a plot of covariates corresponding to all
possible combinations for 𝑟1and 𝑟2 with 𝑁, 𝑝, and 𝑑 again equal to 388, 0.4, and
0.1, respectively.

Figure 4.7.1: Ranking of Covariates with All Possible Combinations of Full
Range of 𝑟1and 𝑟2 where 𝑁 = 388, 𝑝 = 0.4, and 𝑑 = 0.1

66

In a real trial setting, it is likely that there will be less than ten covariates under
consideration. Thus, random subsets are presented:

Figure 4.7.2: Random Subsets of Ten Covariates from Figure 4.7.1

Generally, one would expect to see an “elbow” or plateau which could be used as
the cut point for adjustment. In so doing, one can choose to include only those
covariates falling above the cut point in the final analysis model.

Such

simultaneous consideration of both influence and disparity allows a trialist to find
the optimal balance between the competing goals of modeling a treatment effect
that is both precise and conservative.
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4.8. Discussion
It has been shown that failure to adjust for covariates in a non-inferiority
trial with binary outcomes leads to biased estimates of the treatment effect and
increased type I error.18,27 As such, the issue becomes not whether one should
adjust, but rather which covariates should be included. While many model
selection procedures are theoretically akin to the statistic for influence and tests of
baseline imbalance are theoretically akin to the statistic for disparity, neither
approach considers these effects simultaneously. The proposed statistic allows
for evaluation of the importance of adjustment for each covariate relative to the
others and, when used properly, should result in a better estimate of treatment
effect in terms conservativeness and precision given the available data.
The authors recognize that, like tests of baseline imbalance and other
data-driven approaches to covariate adjustment, the use of this statistic may have
important implications for type I error that should be further quantified in a
multivariate setting. Berger4 has proposed an extension whereby the disparity of
a candidate covariate is calculated as the weighted average of the disparities
within each group formed by the covariates already present in the model. The
practical use of this approach, however, is difficult to explore. The lack of
information present in binary variables leads to highly variable results such that
iterative methods may not be sufficient to assure consistency. Thus, while this has
been evaluated in the context of linear regression3, it remains largely unexplored
68

in the context of binary outcomes. Still, the proposed statistic remains useful as a
diagnostic tool when used in conjunction with other techniques for covariate
selection.
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Chapter 5
Aim 3:
Application of a Joint Statistic for Influence and Disparity in the
Identification of Baseline Covariates Required In Analysis of NonInferiority Trials

Due to the increase in type I error imposed by exclusion of important
prognostic variables in non-inferiority trials, a joint statistic for the importance of
adjusting for a given covariate based on its association with outcome (influence)
and its association with treatment (imbalance) has been developed for use when
important factors are not known a priori. Once the data has been collected, this
statistic can be used to rank the relative importance of adjusting for one covariate
over another, and its distribution can be used to determine the optimal number of
covariates to include in analysis. The goal of the present work is to evaluate the
practicality of this method of covariate selection in the rapid anti-convulsant
medication prior to arrival trial (RAMPART) in terms of changes to treatment
estimates and possible implications for maintenance of type I error.
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5.1 Introduction
The ICH guidelines22 for the use of baseline covariates in clinical trials
states:
“Pre-trial deliberations should identify those covariates and factors
expected to have an important influence on the primary variable(s), and
should consider how to account for these in the analysis in order to
improve precision and to compensate for any lack of balance between
treatment groups. If one or more factors are used to stratify the design, it is
appropriate to account for those factors in the analysis. When the potential
value of an adjustment is in doubt, it is often advisable to nominate the
unadjusted analysis as the one for primary attention, the adjusted analysis
being supportive.”
Thus, according to this guidance, covariates should be specified a priori and those
that are deemed necessary for inclusion should be present in both the
randomization and the analysis. However, potential prognostic factors are not
always known at the start of a trial. Although adjusted analyses offer more power
to detect a treatment difference in superiority trials15-17,26,33, unadjusted analyses
may not necessarily inflate type I error. This does not hold for non-inferiority
designs.
In non-inferiority trials, unadjusted analyses can be plagued by sometimes
dramatic increases in type I error in the presence of important prognostic
variables. According to the author’s previous work27, these rates can be doubled
depending on the sample size, the probability of success in the standard of care
group, the underlying treatment difference, and the covariate’s strength of
association with outcome. Thus, it is necessary to develop an approach to identify
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important prognostic covariates in non-inferiority trials where such factors are not
known a priori. Although much of the statistical literature condemns the use of
data-driven approaches in clinical trials due to the increased probability of
selection bias,1,4.31,32,35,36 such work has been done in the context of the superiority
design and has not been fully investigated in non-inferiority trials.
The two factors contributing to the impact of a covariate on the estimate of
the treatment effect are its association with treatment assignment (i.e., imbalance)
and its association with outcome. If precision is the goal, then a trialist should
adjust for those baseline covariates that are imbalanced across treatment groups,
but if accuracy is the goal, then those covariates that are associated with outcome,
regardless of imbalance, should be included.3,7,32 As Canner7 has illustrated, to
obtain a treatment estimate that is both precise and accurate, these factors must be
considered in tandem. Thus, a joint statistic has been developed to evaluate these
aspects simultaneously for a given covariate in a trial with dichotomous outcome
and has been subsequently extended for use in the non-inferiority setting.28 The
aim of the current research is to evaluate the use of this joint statistic in a practical
clinical trial application.

5.2 Existing Literature
It has been shown that failure to adjust for covariates in a non-inferiority
trial with a non-linear outcome leads to biased estimates of the treatment effect
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and increased type I error.18,27 As such, the issue becomes not whether one should
adjust, but rather which covariates should be considered for inclusion in the
analysis. While many model selection procedures are theoretically akin to the
statistic for influence and tests of baseline imbalance are theoretically akin to the
statistic for disparity, neither approach considers these effects simultaneously.
Canner6 developed a statistic to quantify a covariate’s disparity and influence
given a binary outcome and zero treatment effect, which Beach and Meier3
extended for non-zero treatment effects with continuous outcome. In the author’s
previous paper28, Canner and Beach and Meier’s work were used to develop a
statistic for the non-inferiority framework with binary outcome and non-null
treatment effect. This statistic, which represents the product of statistics for a
covariate’s influence on outcome (𝑍𝐼∗ ) and disparity across treatment groups (𝑍𝐷 ),
can be expressed as follows:
𝑍𝐶 ∗ − 𝑍𝐴 =

𝑍𝐼∗ 𝑍𝐷
√2𝑁

−

(𝑟𝑦1 − 𝑟𝑦2 𝑟12 )√2𝑁 − 3)
2
2
2
− 𝑟𝑦2
− 𝑟12
+ 2𝑟𝑦1 𝑟𝑦2 𝑟12
√1 − 𝑟𝑦1

where
𝑍𝐼∗ =

𝑍𝐷 =

2𝑝𝑟2∗ + 𝑑(𝑟1 + 𝑟2∗ )
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁

𝑁
𝑁
[( 2 ) (1 + 𝑟1 ) − ( 2 )(1 − 𝑟1 )] √2𝑁
√𝑁 2
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= √2𝑁𝑟1

𝑟1 = 𝑟12 = 𝑐𝑜𝑟𝑟(𝑡𝑟𝑡, 𝑐𝑜𝑣)

𝑟2∗ =

2𝑝 + 𝑑
2𝑝 + 𝑑
2 (1 − 2 )
2𝑝 + 𝑑
2

𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√

𝑟𝑦1

1
1
𝑝𝑟1 𝑟2∗ + ( ) 𝑑 + ( ) 𝑑𝑟1 𝑟2∗
2
2
=
√𝑝 + (1) 𝑑 + (1) 𝑑𝑟1 𝑟2∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1 𝑟2∗ − (1) 𝑑 2 − (1) 𝑑 2 𝑟`1 𝑟2∗ − (1) 𝑑 2 𝑟12 𝑟2∗ 2
2
2
4
2
4

𝑟𝑦2

1
1
( ) 𝑑𝑟1 + ( ) 𝑑𝑟2∗ + 𝑝𝑟2∗
2
2
=
1
1
√𝑝 + ( ) 𝑑 + ( ) 𝑑𝑟1 𝑟2∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1 𝑟2∗ − (1) 𝑑 2 − (1) 𝑑 2 𝑟1 𝑟2∗ − (1)𝑑 2 𝑟12 𝑟2∗ 2
2
2
4
2
4

𝑁 = 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 𝑝𝑒𝑟 𝑎𝑟𝑚
𝑝 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑓𝑎𝑖𝑙𝑢𝑟𝑒
𝑑 = 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑒𝑐𝑡
By calculating this statistic for all available covariates in the study data and
ranking, a trialist can evaluate the importance of adjusting for one covariate over
another in a non-inferiority setting. The covariate ranked highest is the most
important one to adjust for and each subsequent covariate becomes less so.28 The
top ranks can then be used in a model building procedure to determine the most
appropriate multivariate model in terms of both the precision of the estimate of
the treatment effect and the extent to which it maintains the type I error.
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5.3 Application
5.3a RAMPART
The

Rapid

Anti-Convulsant

Medication

Prior

to

Arrival

Trial

(RAMPART) was a randomized double dummy phase III clinical trial designed to
test whether intramuscular (IM) midazolam was non-inferior by a margin of 10%
to intravascular (IV) lorazepam for the treatment of status epilepticus,
operationally defined as a seizure lasting at least five minutes without
interruption. Because the disease is life-threatening, the paramedics needed to
administer the treatment immediately upon arrival. Thus, this study was
conducted in an ambulatory setting under exception from informed consent, and
the randomization scheme did not allow for any covariate adjustments.40 Subjects
were well balanced between treatment groups on demographic and clinical
characteristics, and the primary outcome of seizure termination prior to ED arrival
without the use of rescue medication was met for 329 of 448 (73.4%) subjects
allocated to active IM treatment and in 282 of 445 (63.4%) allocated to active IV
treatment (risk difference (RD): 10.1%, 95% CI: 4.0%,16.1%). Thus, the trial
results showed that IM midazolam was actually superior to IV lorazepam.39 The
primary analysis did not adjust for any pre-specified prognostic variables.
However, this secondary analysis explores whether or not the inclusion of some
subset of available covariates may improve the precision and conservativeness of
the treatment effect.
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The statistic for importance was calculated for several potential covariates
of interest including subsequent ICU admission, hospital admission, intubation,
recurrent seizure within 12 hours, hypotension, Hispanic ethnicity, type of
seizure, prior history of seizure, low dose vs high dose, non-white race, pediatric
vs adult, intubation within 30 minutes, recurrent seizure, and gender. Table 5.3a.1
gives the various components of the statistic for importance, including 𝑟1 (the
correlation between treatment and covariate), 𝑟2 (a function of the correlations
between covariate and outcome and treatment and outcome), 𝑍𝐷 (the statistic for
disparity), and 𝑍𝐼∗ (the statistic for influence), as well as the estimate of the
treatment effect on the risk difference scale, including the associated 95%
confidence interval and bias.
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0.0783

0.0091
-0.1308
0.0611

0.0132
-0.0074
-0.0289
0.0086
-0.0094

0.0085
0.0007
-0.0013
-0.0046
-0.0013
-0.0233

Hypotension
Hispanic
Type of Seizure
Prior Hx

Low Dose
Non-White
<18 Yrs of Age
Intubation(30
Mins)
Recurrent
Seizure
Gender

-0.6964

-0.0380

-0.1367

-0.0396

0.0216

0.2536

-0.2805

0.2559

-0.8646

-0.2199

0.3930

-1.4033

-2.4664

-2.4298

𝑍𝐷

*For 95% confidence interval of the treatment effect
**Bias is calculated as 𝛽𝑢𝑛𝑎𝑑𝑗 − 𝛽𝑎𝑑𝑗

0.0194

-0.0003

0.0010

-0.0045

0.0195

-0.0077

-0.0507

-0.1383

-0.1222

-0.0825
-0.0470

-0.1321

-0.0813

𝑟2

Intubation
Recurrent
Seizure (12 Hrs)

ICU Admission
Hospital
Admission

𝑟1

-3.2698
-3.2902

0.7816

-3.2584

-3.2509

-3.2495

-3.2486

-3.2456

-3.2359

-3.2285

-3.2254

-3.1794

-2.7328

-2.3880

-2.3383

Z
Importance

2.7003

-5.7985

0.3980

-0.0130

0.0722

-0.2315

0.8888

-0.4359

-2.2651

3.5059

-6.2676

-5.6757

-6.1057

𝑍𝐼∗

0.0406

0.0403

0.0403

0.0400

0.0399

0.0399

0.0399

0.0397

0.0397

0.0396

0.0390

0.0324

0.0274

0.0267

Lower
Bound*

0.1013

0.1008

0.0999

0.1007

0.1007

0.1007

0.1006

0.1004

0.1004

0.1002

0.0993

0.0920

0.0875

0.0866

Treatment
Estimate

0.1620

0.1612

0.1594

0.1614

0.1614

0.1614

0.1613

0.1611

0.1612

0.1607

0.1596

0.1515

0.1475

0.1464

Upper
Bound*

-0.0007

-0.0001

0.0008

0.0000

0.0000

0.0000

0.0000

0.0002

0.0002

0.0005

0.0014

0.0087

0.0132

0.0141

Bias in the
Treatment
Estimate**

Table 5.3a.1: Statistics and Treatment Estimates by Covariate for RAMPART. Each Model Contained
Treatment Plus One Covariate.

The table is currently sorted by Z Importance, which is a weighted product of
𝑍𝐷 and 𝑍𝐼∗ minus the adjusted Z value. Thus, it represents a joint measure of
disparity and influence. By ranking the covariates in this manner, we are able to
not only identify the most important subset in terms of both the point estimate
itself and its precision, but also to consider covariates relative to each other.
Other rankings can be explored. For example, if one were concerned with
precision, one might choose to rank by 𝑍𝐷 . In this case, hospital admission would
surpass ICU admission as the top ranked covariate. However, if the goal was
accuracy, one might chose to use 𝑍𝐼∗ instead, revealing intubation, ICU admission,
and intubation within 30 minutes. Intubation within 30 minutes is now among our
top three because it has a large 𝑟2 relative to the others. However, if we are
interested in both the point estimate and its precision, we would not want to
choose intubation within 30 minutes as its 𝑟1 is quite small. Figure 5.3a.1
illustrates the impact on the treatment estimate on the risk difference scale when a
specific covariate is included in the model.
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Figure 5.3a.1: Treatment Estimates and 95% Confidence Intervals for Covariates
in RAMPART. Each Model Contains Treatment Plus One Covariate.
Those covariates with high values of 𝑟1 and 𝑟2 in the same direction pull the point
estimate of the treatment effect down (toward the null hypothesis) regardless of
whether that direction is postive or negative, whereas those covariates with
correlations in oppostie directions (i.e., one postive and one negative) pull the
estimate up. Thus, when controlling for type I error is the goal, as it should be
given the increased potential under the non-inferioirty design, those covariates
with correlation not in opposition are ranked highest. For the top ranked
covariates, both the treatment estimate and the variance are reduced and this
reduction is less pronounced as we move through the ranks. Figure 5.3a.2 shows
the values of Z importance for the covariates.
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Figure 5.3a.2: Z Importance for Covariates in RAMPART

The same information that is presented in Figure 5.3a.1 is quantified in Z
Importance. From the “elbow” in the curve, it is clear that two, or perhaps three,
covariates are worth further evaluation.

These are ICU admission, hospital

admission, and intubation. For the analysis model, ICU admission and hospital
admission cannot both be included in the analysis because of the high probability
of co-linearity, so we can choose the higher ranked of these and conduct the
analysis adjusting for ICU admission and intubation. Figure 5.3a.3 illustrates the
unadjusted and adjusted confidence intervals for the treatment effect.
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Fail
To
Reject

Reject

Figure 5.3a.3: Impact of Adjustment Using Z Importance in RAMPART

Although we will never reach the non-inferiority bound set for this trial
(RD = -10%) due to the inherent superiority of IM Midazolam that was confirmed
in the trial, we can see that the adjusted analysis shifts the point estimate toward
the null hypothesis in this setting, protecting against the probability of committing
a type I error. Furthermore, we have discovered a more precise estimate of the
treatment effect in this study.
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5.3b RAMPART Pediatric Population
As the RAMPART study represents the largest prospective clinical trial
experience with prehospital status epilepticus (SE) in children and adolescents, a
secondary analysis was performed to describe and clinically characterize this
unique cohort. Of the 893 subjects in the primary intent to treat analysis, 120
were less than 18 years of age.

As in the primary analysis, the pediatric

population was well balanced across treatment groups in terms of demographic
and clinical characteristics, and the primary outcome of seizure termination prior
to ED arrival without the use of rescue medication was met for 41 of 60 (68.3%)
patients randomized to active IM treatment and 43 of 60 (71.7%) randomized to
active IV (RD: -3.3%, 99% CI=-24.9%, 18.2%). Although the study was not
powered for a secondary analysis of the pediatric population, IM Midazolam did
not indicate superiority over IV Lorazepam as it did in the primary analysis.
However, it did show non-inferiority in that the 99% confidence interval included
the 10% non-inferiority margin.

Furthermore, there were some important

differences favoring IM Midazolam in the pediatric population that were not
evident in the cohort as a whole including lower rates of recurrent seizure,
intubation, and ICU admittance.43 Thus, additional analyses that account for these
covariates may reveal important findings in the cohort in addition to improving
the accuracy and precision of the treatment estimate.
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The statistic for the importance of adjustment was calculated for the same
covariates considered above with the exception of hypotension as none of subjects
in the pediatric population met this criterion. Table 5.3b.1 provides the values of
Z Importance, as well as its components, and the treatment estimates.
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-0.1409
-0.1360
-0.0846
-0.0691
-0.0588
0.0896
-0.0345
-0.0407
0.0000
0.1345
0.0431
0.0668

-0.1038
-0.0933
-0.1097
-0.0834
-0.0949
0.0170
-0.0268
-0.0219
-0.0338
-0.0336
-0.1206
-0.1336

Intubation

Hispanic

ICU Admission
Hospital
Admission
Intubation (30
Mins)

Gender

Type of Seizure

Low Dose

Prior Hx

Non-White
Recurrent
Seizure
Recurrent
Seizure (12 Hrs)
-1.4639

-1.3212

-0.3684

-0.3703

-0.2403

-0.2937

0.1857

-1.0398

-0.9140

-1.2013

-1.0222

-1.1375

𝑍𝐷

*For 95% confidence interval of the treatment effect
**Bias is calculated as 𝛽𝑢𝑛𝑎𝑑𝑗 − 𝛽𝑎𝑑𝑗

𝑟2

𝑟1

1.1720

0.7693

2.2661

0.0135

-0.6733

-0.5665

1.4938

-0.9460

-1.1243

-1.3727

-2.2396

-2.3182

𝑍𝐼∗

0.0928

0.2178

0.2497

0.3934

0.4241

0.4249

0.4482

0.5800

0.5875

0.7059

0.8292

0.8959

Z
Importance

-0.1879

-0.1933

-0.1896

-0.1994

-0.2003

-0.2004

-0.1999

-0.2075

-0.2072

-0.2123

-0.2144

-0.2172

Lower
Bound*

-0.0212

-0.0264

-0.0270

-0.0334

-0.0346

-0.0347

-0.0355

-0.0415

-0.0417

-0.0469

-0.0515

-0.0544

Treatment
Estimate

0.1454

0.1404

0.1355

0.1327

0.1311

0.1311

0.1289

0.1245

0.1238

0.1186

0.1113

0.1084

Upper
Bound*

-0.0121

-0.0069

-0.0063

0.0000

0.0013

0.0013

0.0082
0.0021

0.0084

0.0136

0.0182

Bias in the
Treatment
Estimate**
0.0211

Table 5.3b.1: Statistics and Treatment Estimates by Covariate for Pediatric Sub-Population of RAMPART.
Each Model Contained Treatment Plus One Covariate.

The covariates in Table 5.3b.1 are ranked by Z Importance, which represents a
weighted product of the Z for disparity (𝑍𝐷 ) and the Z for influence (𝑍𝐼∗ ) minus
that adjusted Z value. If one were to evaluate 𝑟1 (or 𝑍𝐷 ) in isolation, recurrent
seizure (and the further refined recurrent seizure within 12 hours) would show the
greatest imbalance across treatment arms.

However, imbalance alone is not

sufficient to justify inclusion of covariates in analysis. In fact, as described
previously, covariates must be both disparate and influential to have important
implications for the treatment effect, and the 𝑟2 (or 𝑍𝐼∗ ) for these are quite low in
comparison to the other available covariates. Similarly, non-white race shows
high influence, but low disparity. Figure 5.3b.1 illustrates this impact for all
available covariates in terms of point estimates and confidence intervals.

Figure 5.3b.1 Treatment Estimates and 95% Confidence Intervals for Covariates
in Pediatric Sub-Population of RAMPART. Each Model Contains Treatment Plus
One Covariate.
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In the pediatric cohort, as with the population as a whole, the covariates with
correlation in the same direction pull the point estimate of the treatment effect
down (towards the null hypothesis), while those with opposing correlations pull it
up. It is those covariates that pull it down which are important to include in order
to maintain type I error. However, the relative impact on the point estimate and
its variance diminishes as we continue to add covariates to the model. Figure
5.3b.2 provides the distribution of the values of Z Importance, which can be used
to determine the best number of covariates for inclusion.

Figure 5.3b.2: Z Importance for Covariates in Pediatric Sub-Population of
RAMPART

The distribution in Figure 5.3b.2 does not show the same plateau effect as in the
combined population of children and adults (Figure 5.3a.2), making the decision
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less obvious. Thus, one might chose to evaluate several models for sensitivity. In
this case, however, the issue of collinearity resurfaces. The top ranked covariates,
in order of importance, are intubation, Hispanic ethnicity, ICU admission, hospital
admission, and intubation within 30 minutes of ED arrival. The top three are
likely to require inclusion, while hospital admission and intubation within 30
minutes are more debatable. As before, in the event of likely collinearity, it is
reasonable to take the higher ranked covariate in each case. Thus, the most
conservative and precise estimate of treatment effect results from adjustment for
intubation, Hispanic ethnicity, and ICU admission. Figure 5.3b.3 provides this
estimate and its 95% confidence interval along with the unadjusted estimate for
comparison.
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Fail
To
Reject

Reject

Figure 5.3b.3: Impact of Adjustment Using Z Importance in Pediatric SubPopulation of RAMPART

The inclusion of intubation, Hispanic ethnicity, and ICU admission provides a
more precise estimate of the treatment effect, and, although the overall finding of
the trial has not been changed, the use of the joint statistic for disparity and
influence has revealed a more conservative model.

5.4 Discussion
Failure to adjust for important covariates in non-inferiority trials can have
serious implications for type I error (claiming a treatment is non-inferior when it
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truly is inferior).18.27 As such, we need to make special efforts to protect against
type I errors when operating under this framework. A statistic for the importance
of including a given covariate in analysis has been previously developed by the
authors and combines information about a covariate’s imbalance across treatment
groups and influence on outcome. This statistic can be calculated for all available
covariates in a trial and used to rank them. Based on the distribution of these
values, an appropriate number of covariates can be selected for inclusion in
analysis. The end result will be an estimate of treatment effect that more precise.
Furthermore, the inclusion of variables based on this method will ensure
conservative estimates in terms of type I error under a non-inferiority study
design.28
When applied to a real trial dataset, the statistic was able to identify those
variables that maximized the tradeoff between changes in the point estimate itself
and its precision and produced conservative estimates of treatment effect.
Although the inclusion of the covariates in analysis did not change the overall
conclusions of either trial, both resulted in a more conservative measure of the
assumed treatment effect.

One limitation of this work is that some of the

covariates under consideration, such as intubation, recurrent seizure, and hospital
or ICU admission, may not necessarily constitute prognostic factors as they were
often obtained after the assessment of primary outcome. Future work needs
evaluate the properties of the statistic for continuous or time to event outcomes
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and formally compare the operating characteristics of this data driven approach to
covariate selection to other available methods, particularly in terms of type I error.
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Chapter 6
Overall Conclusions

This proposed work offers insight into an important issue that has been
overlooked by much the methodological literature in the non-inferiority setting,
namely the impact of covariate adjustment. Too often, trialists have taken the
lessons learned from superiority and applied them directly to the non-inferiority
framework. However, this practice is inherently flawed due to the differential
specification of the hypotheses5, and in fact, for many of the effects found in
superiority, just the opposite is true in non-inferiority. In this setting, failing to
adjust for covariates results in treatment estimates that are biased towards zero
with standard errors that are deflated. This results in some increase in power, but
also in a dramatic increase in type I error rates in the non-inferiority setting.27
This presents a real danger for those trialists who may have unknown covariates
or may prefer unadjusted analyses for parsimony or more straightforward
interpretation.
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In RAMPART, the pre-hospital setting of the intervention made covariate
adjusted randomization impossible. Therefore complete randomization and an
unadjusted primary analysis were conducted.40 However, the current work
suggests that the treatment effect estimate may be more precise and accurate
given a prognostic covariate even if it were unknown to investigators. Results
from Aim 1 suggest that it would have been appropriate to adjust for covariates in
the analysis even if adjustment at randomization was impossible as this results in
unbiased treatment estimates and nominal type I error. Given that no known
covariates were available at the start of the trial, an alternate method may have
been that employed by Aim 2. This data driven approach would have allowed us
to investigate possible covariate effects in the data without knowing their
prognostic value in advance and may have resulted in less extreme increases in
type I error. Just as it is recommended to conduct both intention to treat (ITT)
and per protocol (PP) analyses in non-inferiority trials, trialists may also wish to
present both unadjusted and adjusted analyses according to this method when
covariates are not known in advance. Thus, this proposed dissertation work (1)
quantifies the impact of failing to adjust for covariates in terms of bias, power,
and type I error, (2) develops a data driven joint statistic to quantify the impact of
adjustment for a covariate given its influence and disparity, and (3) evaluates its
potential via practical application.
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